DAC

BC Cancer, part of the Provincial Health Services Authority, Technology Development Office, Data Access Committee (PHSA TDO DAC)

Dac ID Contact Person Email Access Information
EGAC00000000011 Lisa Raeburn lisa [dot] raeburn [at] bccancer [dot] bc [dot] ca No additional information is available

This DAC controls 1537 datasets:

Dataset ID Description Technology Samples
EGAD00000000045 Genomic sequencing and transcriptome shotgun sequencing of a metastatic tumour and its recurrence after drug therapy in a single patient Illumina Genome Analyzer II 1
EGAD00000000046 RNA-SEQ data from 3 recurrent and 1 ovarian primary Granulosa Cell Tumour samples unknown 4
EGAD00000000047 Signal data for from 3 recurrent and 1 ovarian primary Granulosa Cell Tumour samples unknown 4
EGAD00000000048 Sequencing data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample Illumina Genome Analyzer II 1
EGAD00000000049 RNA-SEQ data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample Illumina Genome Analyzer II 1
EGAD00000000114 Whole transcriptome sequence data from 18 ovarian clear-cell carcinoma samples and one TOV21G ovarian clear-cell carcinoma cell line Illumina Genome Analyzer II 1
EGAD00001000057 RNA-Seq analysis Illumina Genome Analyzer II 15
EGAD00001000058 Exome Sequencing analysis Illumina Genome Analyzer II 21
EGAD00001000113 Mutational landscapes of primary triple negative breast cancers - Exomes Illumina Genome Analyzer IIx 108
EGAD00001000115 Mutational landscapes of primary triple negative breast cancers - WGS ABI_SOLID 32
EGAD00001000132 Mutational landscapes of primary triple negative breast cancers - RNA seq Illumina Genome Analyzer IIx 80
EGAD00001000370 This dataset is compromised of 5 sequencing experiments from a single patient with sporadic and recurring parathyroid carcinoma. The samples include whole genome sequence of the primary tumor, the first recurrent tumor and peripheral blood. Whole transcriptome sequence of the first and second recurrent tumors are also included. Illumina HiSeq 2000 5
EGAD00001000669 High-grade serous ovarian cancer (HGSC) is characterized by poor outcome, often attributed to the emergence of treatment-resistant subclones. We sought to measure the degree of genomic diversity within primary, untreated HGSCs to examine the natural state of tumour evolution prior to therapy. We performed exome sequencing, copy number analysis, targeted amplicon deep sequencing and gene expression profiling on 31 spatially and temporally separated HGSC tumour specimens (six patients), including ovarian masses, distant metastases and fallopian tube lesions. We found widespread intratumoural variation in mutation, copy number and gene expression profiles, with key driver alterations in genes present in only a subset of samples (eg PIK3CA, CTNNB1, NF1). On average, only 51.5% of mutations were present in every sample of a given case (range 10.2 to 91.4%), with TP53 as the only somatic mutation consistently present in all samples. Complex segmental aneuploidies, such as whole-genome doubling, were present in a subset of samples from the same individual, with divergent copy number changes segregating independently of point mutation acquisition. Reconstruction of evolutionary histories showed one patient with mixed HGSC and endometrioid histology, with common aetiologic origin in the fallopian tube and subsequent selection of different driver mutations in the histologically distinct samples. In this patient, we observed mixed cell populations in the early fallopian tube lesion, indicating that diversity arises at early stages of tumourigenesis. Our results revealed that HGSCs exhibit highly individual evolutionary trajectories and diverse genomic tapestries prior to therapy, exposing an essential biological characteristic to inform future design of personalized therapeutic solutions and investigation of drug-resistance mechanisms Illumina Genome Analyzer 25
EGAD00001000692 Files associated with the dataset: HS1626.bam, HS1484.bam, HS1483.bam, HS1482.bam, HS1481.bam, HS1480.bam, HS1479.bam, HS1478.bam, A13805.bam, A13800.bam, A13799.bam, A05253.bam, A05252.bam, A13806.bam Illumina Genome Analyzer,Illumina Genome Analyzer II,Illumina HiSeq 2000 12
EGAD00001000702 Complete set of bam files associated with study EGAS00001000622 190
EGAD00001000794 Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is an extremely rare, aggressive cancer affecting children and young women. We identified germline and somatic inactivating mutations in the SWI/SNF chromatin-remodeling gene SMARCA4 in 75% (9/12) of SCCOHT patients in addition to SMARCA4 protein loss in 82% (14/17) of SCCOHT tumors, but in only 0.4% (2/485) of other primary ovarian tumors. These data implicate SMARCA4 in SCCOHT oncogenesis. Illumina HiSeq 2000 11
EGAD00001000850 Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is an extremely rare, aggressive cancer affecting children and young women. We identified germline and somatic inactivating mutations in the SWI/SNF chromatin-remodeling gene SMARCA4 in 75% (9/12) of SCCOHT patients in addition to SMARCA4 protein loss in 82% (14/17) of SCCOHT tumors, but in only 0.4% (2/485) of other primary ovarian tumors. These data implicate SMARCA4 in SCCOHT oncogenesis. Illumina HiSeq 2000 19
EGAD00001000974 High-grade serous ovarian cancer (HGSC) is characterized by poor outcome, often attributed to emergence of treatment-resistant sub-clones. We sought to measure the degree of genomic diversity within primary, untreated HGSC to examine the natural state of tumor evolution prior to therapy. We performed exome sequencing, copy number analysis, targeted amplicon deep sequencing and gene expression profiling on thirty-one spatially and temporally separated HGSC tumor specimens (six patients) including ovarian masses, distant metastases, and fallopian tube lesions. We found widespread intra-tumoral variation in mutation, copy number, and gene expression profiles, with key driver alterations in genes present in only a subset of samples (e.g. PIK3CA, CTNNB1, NF1). On average, only 51.5% of mutations were present in every sample of a given case (range: 10.2% to 91.4%), with TP53 as the only somatic mutation consistently present in all samples. Complex segmental aneuploidies, such as whole genome doubling, were present in a subset of samples from the same individual, with divergent copy number changes segregating independently of point mutation acquisition. Reconstruction of evolutionary histories showed one patient with mixed HGSC and endometrioid histology with common etiologic origin in the fallopian tube and subsequent selection of different driver mutations in the histologically distinct samples. In this patient, we observed mixed cell populations in the early fallopian tube lesion, indicating diversity arises at early stages of tumorigenesis. Our results reveal that HGSC exhibit highly individual evolutionary trajectories and diverse genomic tapestries prior to therapy, exposing an essential biological characteristic to inform future design of personalized therapeutic solutions and investigation of drug resistance mechanisms. Illumina HiSeq 2000,Illumina MiSeq 131
EGAD00001000978 Multi-region whole genome sequencing of an high grade serous ovarian carcinoma sample for characterization of genomic intra-tumoural heterogeneity. Illumina HiSeq 2000 48
EGAD00001001066 Dynamics of genomic clones in breast cancer patient xenografts at single cell resolution Illumina HiSeq 2000,Illumina MiSeq 188
EGAD00001001073 miRNA-seq Cohort of 140 Formalin Fixed Paraffin Embedded Diffuse Large B-cell Lymphoma Patient Samples 140
EGAD00001001074 miRNA-seq Cohort of 92 Fresh Frozen Diffuse Large B-cell Lymphoma Patient Samples 92
EGAD00001001075 miRNA-seq Cohort of 15 Benign Centroblasts 15
EGAD00001001085 This dataset includes 2 pairs of tumour/normal whole genome sequence data as well as MEN1 gene targeted sequencing of an additional 87 specimens. Illumina HiSeq 2500,Illumina MiSeq 91
EGAD00001001226 smRNA-Seq assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada as part of the International Human Epigenome Consortium. 28
EGAD00001001227 Strand-specific mRNA-Seq assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 32
EGAD00001001228 Whole genome shotgun sequencing assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 27
EGAD00001001229 ChIP-Seq (H3K27ac) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48
EGAD00001001230 ChIP-Seq (H3K27me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48
EGAD00001001231 ChIP-Seq (H3K36me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48
EGAD00001001232 ChIP-Seq (H3K4me1) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48
EGAD00001001233 ChIP-Seq (H3K4me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48
EGAD00001001234 ChIP-Seq (H3K9me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48
EGAD00001001235 ChIP-Seq (Input) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 48
EGAD00001001307 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001308 Genome and transcriptome sequence data from a primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study MinION,PromethION 3
EGAD00001001309 Genome and transcriptome sequence data from an appendix cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001310 Genome and transcriptome sequence data from a peritoneal mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001311 Genome and transcriptome sequence data from a peritoneal mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001312 Fastq data for whole genome bisulfite sequencing assays for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 30
EGAD00001001321 This dataset includes WGS & WTS alignment data generated from 1 ATC tumor, its matched peripheral blood specimen and 3 authenticated ATC cell lines, THJ-16T, THJ-21T and THJ-29T. In addition, it includes WTS data from extra 4 unique anaplastic cell lines, ACT-1, C643, HTh7 and T238. Illumina HiSeq 2000,Illumina HiSeq 2500 13
EGAD00001001400 Fastq data for whole genome shotgun sequencing assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 27
EGAD00001001401 Fastq data for smRNA-Seq assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000 28
EGAD00001001402 Fastq data for stranded mRNA-Seq assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 32
EGAD00001001403 Fastq data for ChIP-Seq (H3K27ac) assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 48
EGAD00001001404 Fastq data for ChIP-Seq (H3K27me3) assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 48
EGAD00001001405 Fastq data for ChIP-Seq (H3K36me3) assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 48
EGAD00001001406 Fastq data for ChIP-Seq (H3K4me1) assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 48
EGAD00001001407 Fastq data for ChIP-Seq (H3K4me3) assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 48
EGAD00001001408 Fastq data for ChIP-Seq (H3K9me3) assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 48
EGAD00001001409 Fastq data for ChIP-Seq (Input) assays assay for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000,Illumina HiSeq 2500 48
EGAD00001001417 bam files associated with the study EGAS00001001205 6
EGAD00001001435 Aligned whole genome bisulfite sequencing data for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 30
EGAD00001001439 Mammary cell samples from donors 28/32/33. Contains 12 MiSeq sequencefiles and 12 alignment files derived from HiSeq runs. Illumina MiSeq 12
EGAD00001001467 WGS of 8 trios - affected child and both normal parents 24
EGAD00001001618 Sequence data from two medullary thyroid carcinoma patients: WGS datasets generated from tumors and matched normal tissues and RNA-Seq from tumors are included. Illumina HiSeq 2000,Illumina HiSeq 2500 6
EGAD00001001646 Fastq files corresponding to RNA-Seq dataset for PTPN1 project (EGAS00001000554) Illumina Genome Analyzer,Illumina Genome Analyzer II,Illumina HiSeq 2000 10
EGAD00001001655 Genome and transcriptome sequence data from an atypical teratoid rhabdoid tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001656 Genome and transcriptome sequence data from an atypical chronic lymphocytic leukemia patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001657 Genome and transcriptome sequence data from a parotid gland cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001658 Genome and transcriptome sequence data from an odontogenic ghost cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001876 Genome and transcriptome sequence data from a colorectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study. These data are included in the manuscript entitled, "Response to Angiotensin Blockade with Irbesartan in a Patient with Metastatic Colorectal Cancer". 4
EGAD00001001885 January 2016 update of RNA-Seq data (bams, fastqs) for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 17
EGAD00001001957 March 2016 update of Whole genome bisulfite sequencing assay data (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 18
EGAD00001001958 March 2016 update of whole genome shotgun sequencing data (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 17
EGAD00001001959 March 2016 update of smRNA-Seq assays data (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 20
EGAD00001001961 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 4
EGAD00001001962 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001963 Genome and transcriptome sequence data from a non small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001964 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001965 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001966 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 3
EGAD00001001967 Genome and transcriptome sequence data from an adenocarcinoma of right lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001968 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 2
EGAD00001001969 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001987 March 2016 update of Whole genome bisulfite sequencing assay data (bams) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 18
EGAD00001002017 Genome and transcriptome sequence data from a breast primary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002018 Genome and transcriptome sequence data from a melanoma skin cancer - squamous cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 4
EGAD00001002019 Genome and transcriptome sequence data from a patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002020 Genome and transcriptome sequence data from a metastatic NPC patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002021 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002022 Genome and transcriptome sequence data from a colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002023 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002024 Genome and transcriptome sequence data from an anal rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002025 Genome and transcriptome sequence data from a colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002026 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 4
EGAD00001002027 Genome and transcriptome sequence data from a colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002028 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002029 Genome and transcriptome sequence data from an ovarian granulosa patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002030 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002031 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002032 Genome and transcriptome sequence data from an adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002033 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002034 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002035 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002036 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002037 Genome and transcriptome sequence data from an adrenal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002038 Genome and transcriptome sequence data from a peripheral T-cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 5
EGAD00001002039 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002040 Genome and transcriptome sequence data from a squamous cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002041 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002042 Genome and transcriptome sequence data from an endometrial cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002043 Genome and transcriptome sequence data from a recurrent glioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002044 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002045 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002046 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002047 Genome and transcriptome sequence data from a breast ductal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002048 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002049 Genome and transcriptome sequence data from an adrenal cortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002238 ChIP-Seq (H3K4me3, H3K4me1, H3K9me3, H3K27ac, H3K27me3, H3K36me3, Input) data for HL60 cell line generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency. Illumina HiSeq 2000 1
EGAD00001002239 June 2016 data update (bam/fastq for CEMT0062, CEMT0068, CEMT0072, CEMT0086, CEMT0087 ChIP-Seq and RNA-Seq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 10
EGAD00001002531 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002532 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002533 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002534 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002535 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002536 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002537 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002538 Genome and transcriptome sequence data from a uterine sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002539 Genome and transcriptome sequence data from an oligodendroglioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002540 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002541 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002542 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002543 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002544 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002545 Genome and transcriptome sequence data from a duodenal malignancy patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002546 Genome and transcriptome sequence data from a melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002547 Exome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 4
EGAD00001002548 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002549 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002550 Genome and transcriptome sequence data from a primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002551 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002552 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002553 Genome and transcriptome sequence data from an unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002554 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002555 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002556 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002557 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002558 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002559 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002560 Genome and transcriptome sequence data from a cervical cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002561 Genome and transcriptome sequence data from a metastatic cervical cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002562 Genome and transcriptome sequence data from an osteogenic sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002563 Genome and transcriptome sequence data from a follicular lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002564 Genome and transcriptome sequence data from an adenocarcinoma of lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002565 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 5
EGAD00001002566 Genome and transcriptome sequence data from a uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002567 Genome and transcriptome sequence data from a rectosigmoid adenocarcinoma (colorectal cancer) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002568 Genome and transcriptome sequence data from a metastatic endometrial cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002569 Genome and transcriptome sequence data from a primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002570 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002571 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002572 Genome and transcriptome sequence data from an infiltrating ductal carcinoma of right breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002573 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002574 Genome and transcriptome sequence data from a ductal carcinoma of left breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002575 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002576 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002577 Genome and transcriptome sequence data from an adenocarcinoma of primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002578 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002579 Genome and transcriptome sequence data from a carcinoma of left lower outer quadrant patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002580 Genome and transcriptome sequence data from a right breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002581 Genome and transcriptome sequence data from a metastatic myxofibrosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002582 Genome and transcriptome sequence data from a squamous cell carcinoma of anal canal patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002583 Genome and transcriptome sequence data from a retroperitoneal leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002584 Genome and transcriptome sequence data from a vulvar metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002585 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002586 Genome and transcriptome sequence data from a squamous cell carcinoma of vulva patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002587 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002588 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002589 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002590 Genome and transcriptome sequence data from an adenomacarcinoma of vulva patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002591 Genome and transcriptome sequence data from a neuroendocrine tumor likely pancreatic origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study MinION 2
EGAD00001002592 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002593 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002594 Genome and transcriptome sequence data from a peritoneal mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002595 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the GE junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002596 Genome and transcriptome sequence data from a porocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002597 Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002598 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002599 Genome and transcriptome sequence data from a medullary thyroid carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002600 Genome and transcriptome sequence data from an adnexal tumor probable of Wolffian origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002601 Genome and transcriptome sequence data from an invasive ductal carcinoma of left breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002602 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002603 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002604 Genome and transcriptome sequence data from a clear cell carcinoma of ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002605 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002606 Genome and transcriptome sequence data from an adenocarcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002607 Genome and transcriptome sequence data from a pancreatic cancer (likely PNET) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002608 Genome and transcriptome sequence data from a pleomorphic spindle cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002609 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002610 Genome and transcriptome sequence data from an invasive carcinoma of left breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002611 Genome and transcriptome sequence data from an adenocarcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002612 Genome and transcriptome sequence data from an esophageal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002613 Genome and transcriptome sequence data from a breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002614 Genome and transcriptome sequence data from a thymic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002615 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002616 Genome and transcriptome sequence data from a superficial pleomorphic liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002617 Genome and transcriptome sequence data from a small cell/neuroendocrine carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002618 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002619 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002620 Genome and transcriptome sequence data from a myxoid liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002621 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002622 Genome and transcriptome sequence data from a metastatic colorectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002623 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002624 Genome and transcriptome sequence data from a squamous cell carcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002625 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002626 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002627 Genome and transcriptome sequence data from an adenoid cystic carcinoma of the trachea patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002628 Genome and transcriptome sequence data from a squamous cell carcinoma of anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002629 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002630 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002631 Genome and transcriptome sequence data from a serous endometrial cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002632 Genome and transcriptome sequence data from a testicular cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002633 Genome and transcriptome sequence data from an endometrial carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002634 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002635 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002636 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002637 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002638 Genome and transcriptome sequence data from a metastatic prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002639 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002640 Genome and transcriptome sequence data from a clival chordoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002641 Genome and transcriptome sequence data from a metastatic small cell carcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002642 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002643 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002644 Genome and transcriptome sequence data from a multifocal hepatocellular carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002645 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002646 Genome and transcriptome sequence data from an epithelioid mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002647 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002648 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002724 September 2016 data update (bam/fastq/vcf) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 24
EGAD00001002891 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002896 Amplicon sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are Illumina amplicon deep sequencing libraries (n = 118) to validate somatic predictions made in the whole genome sequencing libraries. Specifically, there are 72 tumor libraries and 46 normal libraries. Some patients may have multiple amplicon libraries sequenced. Illumina HiSeq 2000 118
EGAD00001002897 Whole genome sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are libraries from 41 patients. Specifically: 15 transformed follicular lymphoma (TFL), 6 early progressers (PFL), and 20 non-early progressers (NPFL). For TFL and PFL patients, trios consisting of diagnostic (T1), transformed/progressed (T2) and a matching normal are available (n = 63 libaries in total). For NPFL patients, a tumor-normal pair are available (n = 40 libraries). 103
EGAD00001002898 Oliocapture sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are sequencing libraries from the extension cohort of 277 patients. Specifically, there are 402 tumor libraries and 82 normal libraries. 484
EGAD00001002972 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002973 Genome and transcriptome sequence data from a rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002974 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002975 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma of unknown primary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002976 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002977 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002978 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002979 Genome and transcriptome sequence data from a GI primary (prev breast cancer) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002980 Genome and transcriptome sequence data from a metastatic fibrolamellar hepatocelluar carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002981 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002982 Genome and transcriptome sequence data from a metastatic rectosigmoid adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002983 Genome and transcriptome sequence data from a metastatic carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002984 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002985 Genome and transcriptome sequence data from a adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002986 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002987 Genome and transcriptome sequence data from a metastatic endocervical adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002988 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002989 Genome and transcriptome sequence data from a medullary thyroid cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002990 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002991 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002992 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002993 Genome and transcriptome sequence data from a metastatic carcinoma of primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002994 Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002995 Genome and transcriptome sequence data from a carcinosarcoma of the uterus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002996 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002997 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002998 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002999 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003000 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003001 Genome and transcriptome sequence data from a serous carcinoma of fallopian tube patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003002 Genome and transcriptome sequence data from a metastatic adult granulosa cell tumour patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003003 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003004 Genome and transcriptome sequence data from a glioblastoma multiforme patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003005 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003006 Genome and transcriptome sequence data from a metastatic medullary thyroid cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003007 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003008 Genome and transcriptome sequence data from a metastatic adenocarcinoma presumably of ovarian origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003009 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003010 Genome and transcriptome sequence data from a metastatic uterine leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003011 Genome and transcriptome sequence data from a squamous cell carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003012 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003013 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003014 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003015 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003016 Genome and transcriptome sequence data from a metastatic ductal carcinoma of the breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003017 Genome and transcriptome sequence data from a metastatic large cell neuroendocrine tumour of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003018 Genome and transcriptome sequence data from a metastatic clear cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003019 Genome and transcriptome sequence data from a metastatic uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003020 Genome and transcriptome sequence data from a low grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003021 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003022 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003023 Genome and transcriptome sequence data from a metastatic renal cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003024 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003025 Genome and transcriptome sequence data from an endometrial adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003026 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003027 Genome and transcriptome sequence data from an anaplastic myxopapillary ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003028 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003029 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003030 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003031 Genome and transcriptome sequence data from a metastatic collecting duct kidney cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003032 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003033 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003034 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003035 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003036 Genome and transcriptome sequence data from an ovarian adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003037 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003038 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003039 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003040 Genome and transcriptome sequence data from a chordoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003041 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003042 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003043 Genome and transcriptome sequence data from a breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003044 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003045 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003046 Genome and transcriptome sequence data from a sigmoid cancer and an ampullary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003047 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003048 Genome and transcriptome sequence data from a metastatic pancreatic neuroendocrine tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003049 Genome and transcriptome sequence data from a prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003050 Genome and transcriptome sequence data from a serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003051 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003052 Genome and transcriptome sequence data from a metastatic malignant peripheral nerve sheath tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003053 Genome and transcriptome sequence data from an adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003054 Genome and transcriptome sequence data from a low-grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003055 Genome and transcriptome sequence data from a small bowel carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003056 Genome and transcriptome sequence data from a solitary fibrous tumors (sarcoma) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 2
EGAD00001003057 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003058 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003059 Genome and transcriptome sequence data from a metastatic mullerian tumor of endometrium patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003060 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003061 Genome and transcriptome sequence data from an adenocarcinoma of the distal esophagus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003062 Genome and transcriptome sequence data from an extraosseous osteosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003063 Genome and transcriptome sequence data from an atypical bronchial carcinoid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003064 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003065 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma of the palate patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003066 Genome and transcriptome sequence data from an appendiceal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003067 Genome and transcriptome sequence data from a metastatic gastroesophageal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003068 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003069 Genome and transcriptome sequence data from a pancreatic neuroendocrine tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003070 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003071 Genome and transcriptome sequence data from a pleural mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003072 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003073 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the pancreas patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003074 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003075 Genome and transcriptome sequence data from a metastatic colon caner patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003076 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003077 Genome and transcriptome sequence data from a metastatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003078 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003079 Genome and transcriptome sequence data from a presumed metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003080 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003081 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003082 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003083 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003084 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003085 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003086 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003087 Genome and transcriptome sequence data from a pancreatic neuroendocrine cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003088 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003089 Genome and transcriptome sequence data from a pancreatic neuroendocrine patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003090 Genome and transcriptome sequence data from a metastatic leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003091 Genome and transcriptome sequence data from a clear cell carcinoma of ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003122 December 2016 data update (bam/fastq for WGBS on samples CEMT0062, CEMT0068, CEMT0072, CEMT0086, CEMT0087) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 5
EGAD00001003140 We analyzed the spectrum and clinical significance of MYC and BCL2 mutations in 347 DLBCL cases from population-based cohort of BC, Canada. Illumina MiSeq 347
EGAD00001003148 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for near-diploid immortalized lymphoblastoid cell line GM18507. NextSeq 500 192
EGAD00001003149 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for third-passage patient-derived primary triple-negative breast cancer xenograft SA501X3F. Illumina HiSeq 2500 384
EGAD00001003150 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for fourth-passage patient-derived primary triple-negative breast cancer xenograft SA501X4F. Illumina HiSeq 2500 384
EGAD00001003151 Bulk whole-genome BAM files for 184-hTERT-L2, SA501X3F, and SA501X4F. Illumina HiSeq 2500 3
EGAD00001003152 Microfluidic direct library preparation (DLP) single-cell whole-genome BAM files for near-diploid immortalized breast epithelial cell line 184-hTERT-L2. Illumina HiSeq 2500 192
EGAD00001003265 For CCOC cohorts, OvCaRe cases were reviewed, including frozen material, by at least two expert gynecopathologists prior to inclusion in the sequencing cohort who provided the confirmation on final selected cohort. Frozen H&E from Tokyo were also used for evaluation along with representative H&E photos and review done at the Jikei School of Medicine. All CCOC tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina Genome Analyzer II,Illumina HiSeq 2000 70
EGAD00001003266 For ENOC cohorts, OvCaRe cases were reviewed, including frozen material, by at least two expert gynecopathologists prior to inclusion in the sequencing cohort who provided the confirmation on final selected cohort. Frozen H&E from Tokyo were also used for evaluation along with representative H&E photos and review done at the Jikei School of Medicine. For ENOC, DAH985 and DG1288 are recurrent and both were treated with chemotherapy after their first surgery. DAH123 is a untreated sample, metastasis from an primary endometrial tumour. All HGSC, GCT, CCOC and the rest ENOC tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina HiSeq 2000 58
EGAD00001003267 For GCT cohorts, OvCaRe cases were reviewed, including frozen material, by at least two expert gynecopathologists prior to inclusion in the sequencing cohort who provided the confirmation on final selected cohort. Frozen H&E from Tokyo were also used for evaluation along with representative H&E photos and review done at the Jikei School of Medicine. All GCT tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina HiSeq 2000 20
EGAD00001003268 HGSC cases in the OvCaRe and CRCHUM Tumour Banks were selected according to the following criteria: (i) were administered platinum taxane based therapy; (ii) relapsed within 12 months (365 days) or had at least longer than 4.5 years (1642.5 days) follow-up data; (iii) had at least 50% tumour content by H&E staining and expert pathology review. All cases were re-reviewed by expert pathologists to confirm the diagnosis of HGSC. Germline BRCA1 and BRCA2 was determined for all patients through hereditary cancer screening programs. The design of cases selection as a discovery cohort was engineered to amplify biological differences by selecting cases from the extremes of the outcome distribution. All HGSC tumours are primary tumour samples. Library construction and sequencing Frozen specimens with >50% tumour cellularity (based on initial slide review) were used for cryosectioning and subsequent nucleic acid extraction. Patient tumour and normal blood samples derived from primary, untreated fresh frozen tumour specimens harvested at diagnosis during standard of care debulking surgery. Germline DNA was provided from peripheral blood buffy coat on all specimens except 13 from Tokyo, where non-cancer frozen tissue was used as a germline source. DNA extraction from both matched normal (blood) and tumour samples (frozen tissue) were performed using the QIAamp Blood and Tissue DNA kit (Qiagen) and quantified using a Qbit fluorometer and reagents (high-sensitivity assay). Three lanes of Illumina HiSeq 2500 v4 chemistry for normal samples and five lanes for tumour samples were obtained. The PCR-free protocol was adopted to eliminate the PCR-induced bias and improve coverage across the genome. Illumina HiSeq 2000 118
EGAD00001003272 March 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 8
EGAD00001003293 RNA-Seq and WXS from 6 glioblastoma patients Illumina HiSeq 2500 11
EGAD00001003395 This dataset consists of the exome sequencing data for 30 tumour and germline DNA pairs derived from relapsed/refractory DLBCL. 60
EGAD00001003414 June 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500,NextSeq 500 40
EGAD00001003422 WXS from barcoded cells that are FACS sorted from GBM-719 xenografts, and the germline reference from patient GBM-719. The 4 xenografts are named according to passage (secondary or tertiary) and treatment (vehicle control or temozolomide). Illumina HiSeq 2500 5
EGAD00001003603 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003604 Genome and transcriptome sequence data from a metastatic gallbladder cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003605 Genome and transcriptome sequence data from a metastatic colonic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003606 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003607 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003608 Genome and transcriptome sequence data from a metastatic small cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003609 Genome and transcriptome sequence data from a metastatic serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003610 Genome and transcriptome sequence data from a mullerian mixed tumor with carcinosarcoma of the ovaries patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003611 Genome and transcriptome sequence data from a metastatic cecal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003612 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003613 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003614 Genome and transcriptome sequence data from a metastatic non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003615 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003616 Genome and transcriptome sequence data from an adenocarcimona of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003617 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003618 Genome and transcriptome sequence data from a mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003619 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003620 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003621 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003622 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003623 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003624 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003625 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003626 Genome and transcriptome sequence data from a retroperitoneal mucinous cystic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003627 Genome and transcriptome sequence data from a salivary duct carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003628 Genome and transcriptome sequence data from a metastatic adenocarcinoma of appendiceal origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003629 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003630 Genome and transcriptome sequence data from a radiation-induced pleomorphic sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003631 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003632 Genome and transcriptome sequence data from a chronic lymphocytic leukemia patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003633 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003634 Genome and transcriptome sequence data from a solitary fibrous tumors (sarcoma) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003635 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003636 Genome and transcriptome sequence data from a metastatic paraganglioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003637 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003638 Genome and transcriptome sequence data from a metastatic prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003639 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003640 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003641 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003642 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003643 Genome and transcriptome sequence data from a metastatic cecal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003644 Genome and transcriptome sequence data from a metastatic spindle cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003645 Genome and transcriptome sequence data from an anaplastic ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003646 Genome and transcriptome sequence data from a squamous cell carcinoma of ge junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003647 Genome and transcriptome sequence data from an anal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003648 Genome and transcriptome sequence data from a glioblastoma multiforme patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003649 Genome and transcriptome sequence data from a metastatic colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003650 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003651 Genome and transcriptome sequence data from a metastatic colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003652 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003653 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003654 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003655 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003656 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003657 Genome and transcriptome sequence data from an adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003658 Genome and transcriptome sequence data from a primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 2
EGAD00001003659 Genome and transcriptome sequence data from an ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003660 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003661 Genome and transcriptome sequence data from an advanced adenocarcinoma of lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003662 Genome and transcriptome sequence data from a left cavernous sinus invasive skull meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003663 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003664 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003665 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003666 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003667 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003668 Genome and transcriptome sequence data from a metastatic rhabdomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003669 Genome and transcriptome sequence data from a metastatic mucinous adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003670 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003671 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003672 Genome and transcriptome sequence data from a metastatic clear cell ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003673 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the ge junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 2
EGAD00001003674 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003675 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003676 Genome and transcriptome sequence data from a metastatic adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003677 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003678 Genome and transcriptome sequence data from a thymoma carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003679 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003680 Genome and transcriptome sequence data from a low grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003681 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003682 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003683 Genome and transcriptome sequence data from a metastatic high grade sarcomatous neoplasm nos patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003684 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003685 Genome and transcriptome sequence data from an osterosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003686 Genome and transcriptome sequence data from a metastatic neuroendocrine tumor arising from small bowel patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003687 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003688 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003689 Genome and transcriptome sequence data from a metastatic epitheloid angiomyelolipoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003690 Transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 1
EGAD00001003691 Genome sequence data from a metastatic squamous cell carcinoma of the oropharynx patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003692 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumour patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003693 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003694 Genome and transcriptome sequence data from a pleomorphic sarcomatoid epithelioid carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003695 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003696 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003697 Genome and transcriptome sequence data from a metastatic meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003698 Genome and transcriptome sequence data from a locally advanced right breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003699 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003700 Genome and transcriptome sequence data from a thymic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003701 Genome and transcriptome sequence data from a metastatic myoepithelial carcinoma of parotid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003702 Genome and transcriptome sequence data from a high grade serous carcinoma of the fallopian tube/ovary/peritoneum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003708 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003709 Genome and transcriptome sequence data from a high-grade serous fallopian tube carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003710 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003711 Genome and transcriptome sequence data from a bilateral breast lobular cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003712 Genome and transcriptome sequence data from a primary of unknown origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003713 Genome and transcriptome sequence data from a low-grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003714 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003715 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003716 Genome and transcriptome sequence data from a melanoma of the right buccal mucosa patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003717 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003718 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003719 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003720 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003721 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003722 Genome and transcriptome sequence data from a primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003723 Genome and transcriptome sequence data from a squamous cell carcinoma of the anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003724 Genome and transcriptome sequence data from a T-cell rich B cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003725 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectosigmoid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003726 Genome and transcriptome sequence data from a large-cell neuroendocrine lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003727 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003728 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003729 Genome and transcriptome sequence data from a peripheral T-cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003730 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003731 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003732 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003733 Genome and transcriptome sequence data from a metastatic uterine leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003734 Genome and transcriptome sequence data from a spindle cell carcinoma of the left parotid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003735 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003736 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003737 Genome and transcriptome sequence data from a sinus adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003738 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003739 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003740 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003741 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003742 Genome and transcriptome sequence data from an adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003743 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003744 Genome and transcriptome sequence data from a pleomorphic xanthoastrocytoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003783 Recent studies using next-generation sequencing strategies have described the landscape of genetic alterations in diffuse large B-cell lymphoma (DLBCL). However, little is known about the clinical relevance of recurrent mutations and copy number alterations and their transcriptional footprints. This study examines the frequency, interaction and clinical impact of recurrent genetic aberrations in DLBCL using high-resolution technologies in a large population-based cohort. Illumina HiSeq 2000,Illumina HiSeq 2500 376
EGAD00001003906 October 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500 28
EGAD00001003908 - Six samples from the DEV cell line: 2 controls, 2 transduced with IL4R WT and 2 transduced with IL4R mutant (I242N) - This DEV cell line is not commercially available and was acquired from a colleague in the Netherlands 6
EGAD00001003913 74 CD49f single-cell methylomes are from cord blood of donor1, and 84 from cord blood of donor2. Samples from donor1 have one sequencing lane, and samples from donor2 have five sequencing lanes. This dataset was generated using Post-Bisulfite Adapter Ligation (PBAL), a bisulfite based whole genome protocol. In total this dataset consists of 494 runs. Illumina HiSeq 2500 158
EGAD00001003920 WGS sequence data from cell lines BT-54/BT-88/BT-92/BT-142 7
EGAD00001003955 This dataset comprises single-cell RNA sequencing of the human Lin-CD34+38-45RA-90+49f+ phenotype isolated from 2 normal cord donors. Library preparation was performed following a modified CEL-Seq2 protocol. NextSeq 500 2
EGAD00001003962 January 2018 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. HiSeq X Ten,Illumina HiSeq 2500 34
EGAD00001003963 March 2018 cumulative data release (bams,fastqs) for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency as part of the International Human Epigenome Consortium HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,NextSeq 500 193
EGAD00001003984 Each tumor sample was cut into three pieces, yielding two end-pieces for cryovials and a middle portion placed in 10% buffered formalin. End pieces were homogenized manually and with a paddle blender (Stomacher). All paraffin-embedded blocks, including formalin-fixed tumor samples and molecular-fixed fallopian tubes, were sectioned and stained with hematoxylin and eosin prior to expert histopathological review to confirm the presence of high grade serous carcinoma. Homogenized end pieces were then flash frozen and later used for WGS. For all tumor and matched normal (peripheral blood) samples, DNA was extracted with the Qiagen AllPrep DNA/RNA kit (tumor samples from patients 25,26,28-32) or the Qiagen Blood and Tissue Extraction Kit (tumor samples from patients 1-4,7,9-17, and all blood samples). For all tumor and normal samples, DNA extraction was followed by library construction and sequencing using Illumina HiSeq2500 whole genome shotgun v4 chemistry with paired-end 125bp reads. Illumina HiSeq 2500 89
EGAD00001003985 Each tumor sample was cut into three pieces, yielding two end-pieces for cryovials and a middle portion placed in 10% buffered formalin. End pieces were homogenized manually and with a paddle blender (Stomacher). All paraffin-embedded blocks, including formalin-fixed tumor samples and molecular-fixed fallopian tubes, were sectioned and stained with hematoxylin and eosin prior to expert histopathological review to confirm the presence of high grade serous carcinoma. Homogenized end pieces were then flash frozen, and RNA was extracted using the miRNeasy Mini kit. Nanodrop was used to assess quality (260/280) and quantity. Total RNA samples were also QC checked using the Caliper HT RNA HiSens assay. Samples ranging from 60-255ng RNA were re-arrayed into a 96-well plate. 5'-RACE PCR was carried out as described in "The interface of malignant and immunologic clonal dynamics in high-grade serous ovarian cancer" (Zhang et al.). Briefly, this involved first round and nested PCR with TRB (TCR beta chain) and IGH (immunoglobulin heavy chain) gene-specific primers. The indexed libraries were sequenced on the Illumina HiSeq platform with paired-end 250bp reads using v2 chemistry reagents. Illumina HiSeq 2500,NextSeq 500 442
EGAD00001003986 A total of 192 positions per patient were deeply sequenced in each corresponding tumor sample (including 4 experimental controls and SNVs predicted to originate at each node of the sample phylogeny, see Zhang et al. for details). Genomic DNA templates were used as starting material to generate PCR products. PCR was set up using Phusion DNA polymerase according to the manufacturer’s specifications. The standard PCR conditions used were an initial denaturation at 98C for 30 seconds, followed by 35 cycles of 98C for 10 seconds, 60C for 15 seconds and 72C for 8 seconds, and a final extension at 72C for 10 minutes. PCR products were cleaned up using PCRClean DX beads. Amplicons were pooled by template for sequencing sample preparation. Sample preparation involved a second round of amplification using Phusion DNA polymerase with 6 PCR cycles, with primers specified in Zhang et al. DNA quality was assessed using the Caliper LabChip GX HighSensitivity Assay and DNA quantity was measured using a Qubit dsDNA HS assay kit on a Qubit fluorometer. The indexed libraries were pooled together and sequenced on the Illumina NextSeq500 platform with paired-end 150bp reads using v2 chemistry reagents. NextSeq 500 180
EGAD00001004142 146 DNA samples obtained from 73 DLBCL patients (matching tumor and normal) were sequenced with PCR free 1.0 genome shotgun sequencing. All files are in bam format. 146
EGAD00001004221 WGS and RNA-Seq data from a GBM patient PT-AB0029 Illumina HiSeq 2000 0
EGAD00001004222 WGS and RNA-Seq data from a GBM patient PT-AB6372 Illumina HiSeq 2000,Illumina HiSeq 2500 2
EGAD00001004223 WGS and RNA-Seq data from a GBM patient PT-AH1410 Illumina HiSeq 2000 0
EGAD00001004224 WGS and RNA-Seq data from a GBM patient PT-AK7565 Illumina HiSeq 2500 0
EGAD00001004225 WGS and RNA-Seq data from a GBM patient PT-AL4257 Illumina HiSeq 2000,Illumina HiSeq 2500 2
EGAD00001004226 Genome sequence data from a GBM patient PT-AR3050 Illumina HiSeq 2500 0
EGAD00001004227 WGS and RNA-Seq data from a GBM patient PT-AR5365 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004228 WGS and RNA-Seq data from a GBM patient PT-BK0248 Illumina HiSeq 2500 0
EGAD00001004229 WGS and RNA-Seq data from a GBM patient PT-BM772 Illumina HiSeq 2000 1
EGAD00001004230 WGS and RNA-Seq data from a GBM patient PT-CA2271 Illumina HiSeq 2000,Illumina HiSeq 2500 0
EGAD00001004231 WGS and RNA-Seq data from a GBM patient PT-CM1209 Illumina HiSeq 2000,Illumina HiSeq 2500 2
EGAD00001004232 WGS and RNA-Seq data from a GBM patient PT-DF5919 Illumina HiSeq 2000,Illumina HiSeq 2500 2
EGAD00001004233 WGS and RNA-Seq data from a GBM patient PT-DS9789 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004234 WGS and RNA-Seq data from a GBM patient PT-EV3071 Illumina HiSeq 2000,Illumina HiSeq 2500 0
EGAD00001004235 WGS and RNA-Seq data from a GBM patient PT-FB6711 Illumina HiSeq 2000 1
EGAD00001004236 Genome sequence data from a GBM patient PT-FR7453 0
EGAD00001004237 WGS and RNA-Seq data from a GBM patient PT-GB9186 Illumina HiSeq 2000 0
EGAD00001004238 WGS and RNA-Seq data from a GBM patient PT-GB9483 Illumina HiSeq 2500 0
EGAD00001004239 WGS and RNA-Seq data from a GBM patient PT-GC1519 Illumina HiSeq 2500 1
EGAD00001004240 WGS and RNA-Seq data from a GBM patient PT-GJ3716 Illumina HiSeq 2500 2
EGAD00001004241 WGS and RNA-Seq data from a GBM patient PT-GR2309 Illumina HiSeq 2500 0
EGAD00001004242 WGS and RNA-Seq data from a GBM patient PT-HN6692 Illumina HiSeq 2500 0
EGAD00001004243 WGS and RNA-Seq data from a GBM patient PT-HO0394 Illumina HiSeq 2000,Illumina HiSeq 2500 0
EGAD00001004244 WGS data from a GBM patient PT-HS9105 0
EGAD00001004245 WGS and RNA-Seq data from a GBM patient PT-JB1730 Illumina HiSeq 2000 0
EGAD00001004246 WGS and RNA-Seq data from a GBM patient PT-JE6375 Illumina HiSeq 2000,Illumina HiSeq 2500 0
EGAD00001004247 WGS and RNA-Seq data from a GBM patient PT-JP2405 Illumina HiSeq 2500 0
EGAD00001004248 WGS and RNA-Seq data from a GBM patient PT-JW6420 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004249 WGS and RNA-Seq data from a GBM patient PT-KM5291 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004250 WGS and RNA-Seq data from a GBM patient PT-LC3356 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004251 WGS and RNA-Seq data from a GBM patient PT-LR9369 Illumina HiSeq 2000 0
EGAD00001004252 WGS and RNA-Seq data from a GBM patient PT-LS4891 Illumina HiSeq 2000 0
EGAD00001004253 WGS and RNA-Seq data from a GBM patient PT-MB9777 Illumina HiSeq 2000,Illumina HiSeq 2500 3
EGAD00001004254 WGS and RNA-Seq data from a GBM patient PT-MD9088 Illumina HiSeq 2500 1
EGAD00001004255 WGS and RNA-Seq data from a GBM patient PT-PD6881 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004256 WGS and RNA-Seq data from a GBM patient PT-RD1291 Illumina HiSeq 2000,Illumina HiSeq 2500 0
EGAD00001004257 WGS and RNA-Seq data from a GBM patient PT-RL5404 Illumina HiSeq 2000 1
EGAD00001004258 WGS and RNA-Seq data from a GBM patient PT-RL7940 Illumina HiSeq 2000 0
EGAD00001004259 WGS and RNA-Seq data from a GBM patient PT-RW9277 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004260 WGS and RNA-Seq data from a GBM patient PT-SK0976 Illumina HiSeq 2000,Illumina HiSeq 2500 1
EGAD00001004261 WGS and RNA-Seq data from a GBM patient PT-SO0258 Illumina HiSeq 2000 1
EGAD00001004262 WGS and RNA-Seq data from a GBM patient PT-TM5196 Illumina HiSeq 2500 1
EGAD00001004263 WGS and RNA-Seq data from a GBM patient PT-VO7089 Illumina HiSeq 2000,Illumina HiSeq 2500 0
EGAD00001004264 WGS data from a GBM patient PT-WP9124 Illumina HiSeq 2500 1
EGAD00001004300 June 2018 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. HiSeq X Ten,Illumina HiSeq 2500 4
EGAD00001004552 10X genomics chromium single-cell RNA-sequencing of (i) patient derived triple negative breast cancer xenograft (ii) primary tumour and ascites ovarian cancer cell lines at tumour recurrence. NextSeq 550 3
EGAD00001004553 Direct library preparation+ single-cell DNA-sequencing of (i) patient derived triple negative breast cancer xenograft (ii) primary tumour and ascites ovarian cancer cell lines at tumour recurrence. Illumina HiSeq 2500 980
EGAD00001004585 NA Illumina HiSeq 2500,NextSeq 500 40
EGAD00001004596 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004597 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004598 Genome and transcriptome sequence data from a mucinous colloid carcinoma of the pancreas patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004599 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004600 Genome and transcriptome sequence data from a non-small cell adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004601 Genome and transcriptome sequence data from a metastatic leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004602 Genome and transcriptome sequence data from a metastatic synovial sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004603 Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of the cheek patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004604 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004605 Genome and transcriptome sequence data from a metastatic choroidal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004606 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study MinION,PromethION 2
EGAD00001004607 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004608 Genome and transcriptome sequence data from a clear cell carcinoma of the left ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004609 Genome and transcriptome sequence data from a low grade chondrosarcoma (bronchus) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004610 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004611 Genome and transcriptome sequence data from a follicular lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004612 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004613 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004614 Genome and transcriptome sequence data from a metastatic follicular thyroid carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004615 Genome and transcriptome sequence data from a ganglioglioma of the left temporal lobe patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004616 Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of the cervix patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004617 Genome and transcriptome sequence data from a anorectal gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004618 Genome and transcriptome sequence data from a metastatic mmmt of the endometrium patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004619 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the stomach patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004620 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004621 Genome and transcriptome sequence data from a metastatic basal cell carcinoma of frontal scalp patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004622 Genome and transcriptome sequence data from a metastatic rectosigmoid cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001004623 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004624 Genome and transcriptome sequence data from a double-hit lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004625 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004626 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004627 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectosigmoid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001004628 Genome and transcriptome sequence data from a osteosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004629 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004630 Genome and transcriptome sequence data from a metastatic basal cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004631 Genome and transcriptome sequence data from a metastatic breast cancer ER+ patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004632 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004633 Genome and transcriptome sequence data from a metastatic renal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004634 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004635 Genome and transcriptome sequence data from a extramedullary spinal ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004636 Genome and transcriptome sequence data from a metastatic endometrioid/mucinous ovarian carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004637 Genome and transcriptome sequence data from a metastatic clear cell carcinoma of gynecological origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004638 Genome and transcriptome sequence data from a high grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004639 Genome and transcriptome sequence data from a metastatic leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004640 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the pancreas patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004641 Genome and transcriptome sequence data from a metastatic alveolar soft part sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004642 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004643 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004644 Genome and transcriptome sequence data from a metastatic lung adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004645 Genome and transcriptome sequence data from a metastatic fibrosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004646 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001004647 Genome and transcriptome sequence data from a metastatic uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004648 Genome and transcriptome sequence data from a high grade sarcoma of the epithelioid/spindle cell patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004649 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004650 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004651 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004652 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the stomach patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004653 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004654 Genome and transcriptome sequence data from a breast invasive ductal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004655 Genome and transcriptome sequence data from a locally advanced oropharyngeal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004656 Genome and transcriptome sequence data from a primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004657 Genome and transcriptome sequence data from a metastatic ampullar carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004658 Genome and transcriptome sequence data from a metastatic osteosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004659 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004660 Genome and transcriptome sequence data from a metastatic primitive neuro-ectodermal tumor of the testicle patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004661 Genome and transcriptome sequence data from a metastatic clear cell carcinoma of the ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004662 Genome and transcriptome sequence data from a metastatic leiomyosarcoma of pancreas patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004663 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the pancreas patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004664 Genome and transcriptome sequence data from a neuroendocrine carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004665 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004666 Genome and transcriptome sequence data from a metastatic pancreatic neck adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004667 Genome and transcriptome sequence data from a metastatic uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004668 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the esophagus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004669 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004670 Genome and transcriptome sequence data from a metastatic spindle cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004671 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004672 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004673 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004674 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004675 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004676 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004677 Genome and transcriptome sequence data from a metastatic colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004678 Genome and transcriptome sequence data from a metastatic thymic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004679 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004680 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004681 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004682 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004683 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004684 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the GE junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004685 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004686 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004687 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004688 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004689 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004690 Genome and transcriptome sequence data from a angiosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004691 Genome and transcriptome sequence data from a metastatic transverse colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004692 Genome and transcriptome sequence data from a metastatic non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004693 Genome and transcriptome sequence data from a metastatic carcinoma to paraspinal mass with primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004694 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004695 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study MinION,PromethION 2
EGAD00001004696 Genome and transcriptome sequence data from a peripheral T-cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004697 Genome and transcriptome sequence data from a low-grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004698 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004699 Genome and transcriptome sequence data from a lung adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004700 Genome and transcriptome sequence data from a metastatic lung adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004701 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004702 Genome and transcriptome sequence data from a high grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004703 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004704 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004705 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004706 Genome and transcriptome sequence data from a adenocarcinoma of the liver patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004707 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004708 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004709 Genome and transcriptome sequence data from a metastatic high-grade adenocarcinoma of the fallopian tubes patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004710 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004711 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004713 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004714 Genome and transcriptome sequence data from a metastatic non-small cell lung adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004715 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004716 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004717 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004718 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004719 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1340 samples; filetype=bam Illumina HiSeq 2500 1340
EGAD00001004720 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 2057 samples; filetype=bam Illumina HiSeq 2500 2057
EGAD00001004721 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1970 samples; filetype=bam Illumina HiSeq 2500 1970
EGAD00001004722 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 2091 samples; filetype=bam Illumina HiSeq 2500 2091
EGAD00001004723 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1267 samples; filetype=bam Illumina HiSeq 2500 1267
EGAD00001004724 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 230 samples; filetype=bam Illumina HiSeq 2500 230
EGAD00001004725 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 232 samples; filetype=bam Illumina HiSeq 2500 232
EGAD00001004726 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 239 samples; filetype=bam Illumina HiSeq 2500 239
EGAD00001004727 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 692 samples; filetype=bam Illumina HiSeq 2500 692
EGAD00001004728 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 612 samples; filetype=bam Illumina HiSeq 2500 612
EGAD00001004729 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1700 samples; filetype=bam Illumina HiSeq 2500 1700
EGAD00001004730 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 628 samples; filetype=bam Illumina HiSeq 2500 628
EGAD00001004731 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 596 samples; filetype=bam Illumina HiSeq 2500 596
EGAD00001004732 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1735 samples; filetype=bam Illumina HiSeq 2500 1735
EGAD00001004733 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 585 samples; filetype=bam NextSeq 550 585
EGAD00001004734 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 766 samples; filetype=bam NextSeq 550 766
EGAD00001004735 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 2055 samples; filetype=bam Illumina HiSeq 2500 2055
EGAD00001004736 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 620 samples; filetype=bam Illumina HiSeq 2500 620
EGAD00001004737 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 624 samples; filetype=bam NextSeq 550 624
EGAD00001004738 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 481 samples; filetype=bam NextSeq 550 481
EGAD00001004739 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 378 samples; filetype=bam Illumina HiSeq 2500 378
EGAD00001004740 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 735 samples; filetype=bam Illumina HiSeq 2500 735
EGAD00001004741 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 718 samples; filetype=bam Illumina HiSeq 2500 718
EGAD00001004742 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 493 samples; filetype=bam NextSeq 550 493
EGAD00001004743 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1222 samples; filetype=bam Illumina HiSeq 2500 1222
EGAD00001004744 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 522 samples; filetype=bam Illumina HiSeq 2500 522
EGAD00001004745 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 488 samples; filetype=bam Illumina HiSeq 2500 488
EGAD00001004746 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 509 samples; filetype=bam NextSeq 550 509
EGAD00001004747 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 604 samples; filetype=bam NextSeq 550 604
EGAD00001004748 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 626 samples; filetype=bam NextSeq 550 626
EGAD00001004749 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 635 samples; filetype=bam Illumina HiSeq 2500 635
EGAD00001004750 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1522 samples; filetype=bam HiSeq X Five 1522
EGAD00001004751 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 465 samples; filetype=bam NextSeq 550 465
EGAD00001004752 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 606 samples; filetype=bam Illumina HiSeq 2500 606
EGAD00001004753 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 615 samples; filetype=bam NextSeq 550 615
EGAD00001004754 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 636 samples; filetype=bam NextSeq 550 636
EGAD00001004755 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 968 samples; filetype=bam HiSeq X Five 968
EGAD00001004756 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 480 samples; filetype=bam NextSeq 550 480
EGAD00001004757 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 561 samples; filetype=bam NextSeq 550 561
EGAD00001004758 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 844 samples; filetype=bam HiSeq X Five 844
EGAD00001004759 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 928 samples; filetype=bam HiSeq X Five 928
EGAD00001004760 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 635 samples HiSeq X Five 635
EGAD00001004761 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1072 samples HiSeq X Five 1072
EGAD00001004762 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1436 samples; filetype=bam HiSeq X Five 1436
EGAD00001004763 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 589 samples; filetype=bam HiSeq X Five 589
EGAD00001004764 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 656 samples; filetype=bam HiSeq X Five 656
EGAD00001004765 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 648 samples; filetype=bam HiSeq X Five 648
EGAD00001004766 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 375 samples; filetype=bam HiSeq X Five 375
EGAD00001004767 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 755 samples; filetype=bam HiSeq X Five 755
EGAD00001004768 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 492 samples; filetype=bam HiSeq X Five 492
EGAD00001004769 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 531 samples; filetype=bam HiSeq X Five 531
EGAD00001004770 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1222 samples; filetype=bam HiSeq X Five 1063
EGAD00001004771 Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 522 samples; filetype=bam HiSeq X Five,Illumina HiSeq 2500 742
EGAD00001004812 40 samples; filetype=bam Illumina HiSeq 2500 40
EGAD00001004813 48 samples; filetype=bam Illumina HiSeq 2500 48
EGAD00001004814 50 samples; filetype=bam Illumina HiSeq 2500 50
EGAD00001004815 45 samples; filetype=bam Illumina HiSeq 2500 45
EGAD00001004816 61 samples; filetype=bam Illumina HiSeq 2500 61
EGAD00001004817 68 samples; filetype=bam Illumina HiSeq 2500 68
EGAD00001004818 71 samples; filetype=bam Illumina HiSeq 2500 71
EGAD00001004819 48 samples; filetype=bam Illumina HiSeq 2500 48
EGAD00001004820 52 samples; filetype=bam Illumina HiSeq 2500 52
EGAD00001004821 60 samples; filetype=bam Illumina HiSeq 2500 60
EGAD00001004822 55 samples; filetype=bam Illumina HiSeq 2500 55
EGAD00001004897 Genome and transcriptome sequence data from a locally advanced breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004898 Genome and transcriptome sequence data from a metastatic rectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004899 Genome and transcriptome sequence data from a invasive ductal carcinoma of right breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004900 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004901 Genome and transcriptome sequence data from a metastatic leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004902 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004903 Genome and transcriptome sequence data from a squamous cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004904 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 2
EGAD00001004905 Genome and transcriptome sequence data from a metastatic adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004906 Genome and transcriptome sequence data from a diffuse large B-cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004907 Genome and transcriptome sequence data from a T-cell prolymphocytic leukemia patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004908 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004909 Genome and transcriptome sequence data from a metastatic serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004910 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004911 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004912 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004913 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004914 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004915 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004916 Genome and transcriptome sequence data from a metastatic leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004917 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004918 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004919 Genome and transcriptome sequence data from a abdominal sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004920 Genome and transcriptome sequence data from a meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004921 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma of the breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004922 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004923 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 3
EGAD00001004924 Genome and transcriptome sequence data from a metastatic neuroendocrine tumor, lung primary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004925 Genome and transcriptome sequence data from a metastatic choroidal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004926 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004927 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004928 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004929 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004930 Genome and transcriptome sequence data from a metastatic ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004931 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004932 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004933 Genome and transcriptome sequence data from a metastatic sarcomatoid carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001004934 Genome and transcriptome sequence data from a squamous cell carcinoma of the alveolar ridge patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001004935 Genome and transcriptome sequence data from a oligometastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001004936 Genome and transcriptome sequence data from a metastatic rectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001004950 March 2019 data update for cord blood CD34+CD38-, CMP, GMP, MEP, monocyte, erythroid precursor, B cell and primary AML total blasts reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency as part of the International Human Epigenome Consortium. This dataset contains data for samples: CEMT0158 CEMT0159 CEMT0160 CEMT0161 CEMT0162 CEMT0163 CEMT0164 CEMT0165 CEMT0166 CEMT0167 CEMT0168 CEMT0169 CEMT0170 CEMT0171 CEMT0172 CEMT0189 HiSeq X Ten,Illumina HiSeq 2500 16
EGAD00001004962 Amplicon sequencing of 10 patients 95
EGAD00001004992 H3K27me3 ChIP-Seq of 6 samples and H3K27ac ChIP-Seq of 4 samples with respective input controls Illumina HiSeq 2500 20
EGAD00001004993 Ribodepletion RNA-Seq of 8 samples and polyA RNA-Seq of 22 samples Illumina HiSeq 2500 30
EGAD00001004994 WXS of 3 samples Illumina HiSeq 2500 3
EGAD00001005060 May 2019 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. HiSeq X Ten,Illumina HiSeq 2500 8
EGAD00001005141 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005142 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005143 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005144 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005145 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005146 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 24 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005147 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005148 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005149 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005150 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 36 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005151 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 36 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005152 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 24 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005153 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 24 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005154 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005155 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005156 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 24 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005157 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 24 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005158 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005159 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005160 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005161 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005162 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005163 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005164 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005165 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 3 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005166 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005167 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005168 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005169 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005170 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005171 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005172 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005173 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005174 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005175 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005176 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005177 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005178 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005179 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005180 Single-cell RNA-sequencing data generated using the 10X genomics chromium platform, comprising patient derived xenograft, cell line, and primary tumour data. This includes different digestion conditions (37C collagenase vs 6C cold protease) and FACS sorting for live, dying, and dead cells. 12 samples; filetype=fastq Illumina HiSeq 2000 1
EGAD00001005316 Next generation RNA-Sequencing (RNA-seq) is a flexible approach that can be applied to e.g. global quantification of transcript expression, the characterization of RNA structure such as splicing patterns and profiling of expressed mutations. Many RNA-seq protocols require up to microgram levels of total RNA input amounts to generate high quality data, and thus remain impractical for the limited starting material amounts typically obtained from rare cell populations, such as those from early developmental stages or from laser micro-dissected clinical samples. Here, we present an assessment of the contemporary ribosomal RNA depletion-based protocols, and identify those that are suitable for inputs as low as 1-10 ng of intact total RNA and 100-500 ng of partially degraded RNA from formalin-fixed paraffin-embedded tissues. Illumina HiSeq 2500,Illumina MiSeq 3
EGAD00001005335 August 2019 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. HiSeq X Ten,Illumina HiSeq 2500 17
EGAD00001005338 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96146A 1195 samples; filetype=bam HiSeq X Five 3
EGAD00001005340 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96172B 1694 samples; filetype=bam HiSeq X Five 3
EGAD00001005345 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96226B 1274 samples; filetype=bam HiSeq X Five 4
EGAD00001005347 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96193B 2410 samples; filetype=bam HiSeq X Five 3
EGAD00001005348 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96199A 843 samples; filetype=bam HiSeq X Five 3
EGAD00001005353 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96199B 1170 samples; filetype=bam HiSeq X Five 3
EGAD00001005354 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96211C 1397 samples; filetype=bam HiSeq X Five 3
EGAD00001005355 Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96225C 1034 samples; filetype=bam HiSeq X Five 2
EGAD00001005419 Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma and is notorious for its clinical heterogeneity. Patient outcomes can be predicted by cell-of-origin (COO) classification, demonstrating that the underlying transcriptional signature of malignant B-cells informs biological behavior in the context of standard combination chemotherapy regimens. In the current study, we used mass cytometry (CyTOF) to examine tumor phenotypes at the protein level with single cell resolution in a collection of 27 diagnostic DLBCL biopsy specimens from treatment naïve patients. We found that malignant B-cells from each patient occupied unique regions in 37-dimensional phenotypic space with no apparent clustering of samples into discrete subtypes. Interestingly, variable MHC class II expression was found to be the greatest contributor to phenotypic diversity. Within individual tumors, a subset of cases showed multiple phenotypic subpopulations, and in one case we were able to demonstrate direct correspondence between protein-level phenotypic subsets and DNA mutation-defined subclones. In summary, CyTOF analysis can resolve both inter- and intra-tumoral heterogeneity among primary samples, and reveals that each case of DLBCL is unique and may be comprised of multiple, genetically distinct subclones. 17
EGAD00001005739 Single-cell gene expression was profiled for 22 Hodgkin lymphoma tumors and 5 reactive lymph nodes (2 replicates were performed for RLN-1). Library preparation was performed with the 10x Chromium platform (3' version 2 assay). Sequencing was performed on an Illumina NextSeq. The BAM files were generated from the raw sequencing data using Cell Ranger (v2.1.0) mkfastq and count commands. Illumina HiSeq 2500 28
EGAD00001005763 Genome and transcriptome sequence data from a metastatic pancreatic neuroendocrine patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study PromethION 3
EGAD00001005769 Interstitial deletion of the long arm of chromosome 5 (del(5q)) is the commonest structural genomic variant in myelodysplastic syndromes (MDS). Lenalidomide (LEN) is the treatment of choice for patients with del(5q) MDS, but half of the responding patients become resistant within two years. TP53 mutations are detected in ~20% of patients who become resistant to LEN. Our data show that patients who become resistant to LEN harbor either TP53 or RUNX1 mutations or loss of RUNX1 expression. Here we show that LEN-induced degradation of IKZF1 permits a RUNX1/GATA2 complex to drive megakaryocytic differentiation and consequent del(5q) MDS progenitor cell death via CRBN-mediated CSNK1A1 degradation. Overexpression of GATA2 is able to restore LEN sensitivity in the context of RUNX1 or TP53 mutations by enhancing LEN-induced megakaryocytic differentiation. Screening for TP53 and RUNX1 mutations or downregulation should identify patients resistant to LEN, and strategies to activate GATA2 may resensitize del(5q) MDS cells to LEN. 16
EGAD00001005780 Whole-exome sequencing for 95 PMBCL cases (including 21 with matching normal DNA) was performed using a targeted capture approach with the SureSelect Human All Exon V6+UTR bait (Agilent Technologies) followed by massively parallel sequencing of enriched fragments on the HiSeq2500 platform (Illumina). Five libraries were pooled per lane and a 125bp paired-end mode was used. Tumor and normal DNA samples were sequenced to an average of 115X (SD 24X). All reads were aligned to the human reference genome (hg19) using bwa-mem version 0.7.5a29 with optical and PCR duplicates removed using the Picard tool. 116
EGAD00001005823 Genome and transcriptome sequence data from a breast ductal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005824 Genome and transcriptome sequence data from an uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005825 Genome and transcriptome sequence data from a metastatic rectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005826 Genome and transcriptome sequence data from a colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005827 Genome and transcriptome sequence data from a primary unknown- upper GI or pulmonary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005828 Genome and transcriptome sequence data from a metastatic choroidal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005829 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005830 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005831 Genome and transcriptome sequence data from a poorly differentiated adenocarcinoma more consistent with metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005832 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005833 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005834 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005835 Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of the esophagus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005836 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005837 Genome and transcriptome sequence data from a metastatic adenocarcinoma of unknown primary (upper GI?) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005838 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005839 Genome and transcriptome sequence data from a metastatic choroid melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005840 Genome and transcriptome sequence data from a carcinoma primary unknown origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005841 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005842 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005843 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005844 Genome and transcriptome sequence data from a metastatic adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005845 Genome and transcriptome sequence data from a metastatic unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005846 Genome and transcriptome sequence data from a cavernous sinus meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005847 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005848 Genome and transcriptome sequence data from a chondrosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005849 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005850 Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001005851 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005852 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005853 Genome and transcriptome sequence data from a lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005854 Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005855 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005856 Genome and transcriptome sequence data from a cervical adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005857 Genome and transcriptome sequence data from a sex-cord stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005858 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005859 Genome and transcriptome sequence data from an endometrioid ovary carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005860 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005861 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005862 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005863 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005864 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005865 Genome and transcriptome sequence data from a tongue squamous cell carcinoma (head and neck) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005866 Genome and transcriptome sequence data from a neuroendocrine tumor (GIC) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005867 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005868 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005869 Genome and transcriptome sequence data from a transformed diffuse large B cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005870 Genome and transcriptome sequence data from an osteosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005871 Genome and transcriptome sequence data from a chordoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005875 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005876 Genome and transcriptome sequence data from a colorectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005877 Genome and transcriptome sequence data from a malignant epithelial mesothelioma (THR) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005878 Genome and transcriptome sequence data from a melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005879 Genome and transcriptome sequence data from an ovarian cystadenocarcinoma low grade patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005880 Genome and transcriptome sequence data from a lung adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005881 Genome and transcriptome sequence data from a colorectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005882 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005883 Genome and transcriptome sequence data from a malignant choroid melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005884 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005885 Genome and transcriptome sequence data from a large intestine-colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005886 Genome and transcriptome sequence data from a colorectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005887 Genome and transcriptome sequence data from a parotid gland adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005888 Genome and transcriptome sequence data from a breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005889 Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005890 Genome and transcriptome sequence data from a melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005891 Genome and transcriptome sequence data from a thyroid hurthle cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005892 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005893 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005894 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005895 Genome and transcriptome sequence data from a cecum adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005896 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005897 Genome and transcriptome sequence data from a metastatic adrenocortical cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005898 Genome and transcriptome sequence data from a malignant peripheral nerve sheath tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005899 Genome and transcriptome sequence data from an endometrial stromal sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005900 Genome and transcriptome sequence data from a hemangioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005901 Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005902 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005903 Genome and transcriptome sequence data from a metastatic gallbladder adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005904 Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005905 Genome and transcriptome sequence data from an adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005906 Genome and transcriptome sequence data from a metastatic clear cell carcinoma of the ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005907 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005908 Genome and transcriptome sequence data from a squamous cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005909 Genome and transcriptome sequence data from an alveolar soft part sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005910 Genome and transcriptome sequence data from a gastroesophageal junction adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005911 Genome and transcriptome sequence data from a colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005912 Genome and transcriptome sequence data from an unknown tissue unknown histology patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001005913 Genome and transcriptome sequence data from an osteosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001006066 Maps of H3K27ac from normal 2nd- and 3rd-trimester cytotrophoblasts, preterm severe preeclampsia cytotrophoblasts, and 2nd-trimester amnion. Maps of H3K27me3, H3K27me3, H3K36me3, and H3K4me1 from 2nd- and 3rd-trimester cytotrophoblast. Maps of H3K9me3 from 2nd- and 3rd-trimester cytotrophoblast, smooth chorion, and basal plate. RNA-seq from 2nd- and 3rd-trimester cytotrophoblasts. Illumina HiSeq 2000,Illumina HiSeq 2500 32
EGAD00001006087 18 DLBCL genomes 18
EGAD00001006142 NA Illumina HiSeq 2000 9
EGAD00001006143 NA Illumina HiSeq 2000 29
EGAD00001006159 Tumor and normal exomes for 51 MCL patients and tumor and normal genomes for 34 MCL patients. 170
EGAD00001006220 February 2020 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. HiSeq X Ten,Illumina HiSeq 2500 28
EGAD00001006221 This dataset contains merged data from the 22 Hodgkin lymphoma and 5 reactive lymph node samples, including count data and cell cluster assignments. 28
EGAD00001006268 RNAseq BAM files for Coding and non-coding mantle cell lymphoma driver mutations 102
EGAD00001006280 Endometrial carcinoma, the most common gynecologic cancer, develops from endometrial epithelium which is composed of secretory and ciliated cells. Pathologic classification is unreliable and there is a need for prognostic tools. We used single cell sequencing to study organoid model systems derived from normal endometrial endometrium to discover novel markers specific for endometrial ciliated or secretory cells. We performed single cell sequencing on endometrial and ovarian tumours, and on organoids both treated with DBZ and normal and found both secretory-like and ciliated-like tumour cells. NextSeq 550 18
EGAD00001006328 Tumor and matching normal exomes for 28 GZL cases (n=56) and targeted capture sequencing for 42 GZL cases with 3 matching normals and 2 pooled normals (n=47) 103
EGAD00001006383 August 2020 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. HiSeq X Ten,Illumina HiSeq 2500 4
EGAD00001006460 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0006_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006461 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0080_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006462 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0080_002 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006463 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0141_004 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006464 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0142_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006465 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0142_003 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006466 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0146_002 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006467 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0149_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006468 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0149_002 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006469 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0150_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006470 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0150_002 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006471 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0152_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006472 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0152_002 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006473 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0163_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006474 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0163_002 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006475 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0172_001 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006476 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0172_002 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006477 Transcriptome profiling by high-throughput sequencing for single cells for library TENX062 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006478 Transcriptome profiling by high-throughput sequencing for single cells for library SCRNA10X_SA_CHIP0063_000 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006479 Transcriptome profiling by high-throughput sequencing for single cells for library TENX064 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006480 Transcriptome profiling by high-throughput sequencing for single cells for library TENX065 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006481 Transcriptome profiling by high-throughput sequencing for single cells for library TENX066 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006482 Transcriptome profiling by high-throughput sequencing for single cells for library TENX068 1 samples; filetype=fastq Illumina HiSeq 2500 1
EGAD00001006483 Transcriptome profiling by high-throughput sequencing for single cells for library TENX069 1 samples; filetype=fastq NextSeq 550 1
EGAD00001006537 NA NextSeq 500 12
EGAD00001006701 As more clinically-relevant genomic features of myeloid malignancies are revealed, it has become clear that targeted clinical genetic testing is inadequate for risk stratification. Here, we developed and validated a clinical transcriptome-based assay for stratification of acute myeloid leukemia (AML). Comparison of RNA-Seq to whole genome and exome sequencing revealed that as a standalone assay, RNA-Seq offered the greatest diagnostic return, enabling identification of expressed gene fusions, single nucleotide and short insertion/deletion variants, and whole-transcriptome expression information. Expression data were used to develop a novel risk score which, when combined with molecular risk guidelines, allowed for the re-stratification of 22.1 to 25.3% of AML patients from three independent cohorts into correct risk groups. Within the adverse-risk subgroup, we identified a subset of patients characterized by dysregulated integrin signaling and RUNX1 or TP53 mutation. We show that these patients may benefit from therapy with inhibitors of focal adhesion kinase (PTK2), demonstrating additional utility of transcriptome-based testing for therapy selection in myeloid malignancy. 275
EGAD00001006939 Whole genome sequencing for single cells for library A95629A 1023 cells; filetype=bam HiSeq X Five 5
EGAD00001006940 Whole genome sequencing for single cells for library A95654B 1740 cells; filetype=bam HiSeq X Five 5
EGAD00001006941 Whole genome sequencing for single cells for library A95673A 1446 cells; filetype=bam NextSeq 550 9
EGAD00001006942 Whole genome sequencing for single cells for library A95703B 1267 cells; filetype=bam HiSeq X Five 5
EGAD00001006943 Whole genome sequencing for single cells for library A95728A 876 cells; filetype=bam HiSeq X Five 5
EGAD00001006944 Whole genome sequencing for single cells for library A96192B 1304 cells; filetype=bam HiSeq X Five 5
EGAD00001006945 Whole genome sequencing for single cells for library A96217B 1616 cells; filetype=bam HiSeq X Five 6
EGAD00001006946 Whole genome sequencing for single cells for library A96219B 1743 cells; filetype=bam HiSeq X Five 7
EGAD00001006947 Whole genome sequencing for single cells for library A98269B 1609 cells; filetype=bam HiSeq X Five 7
EGAD00001006990 JAGuaR outputs from RNA-seq of 35 pancreatic neuroendocrine neoplasms. Illumina HiSeq 2500 35
EGAD00001006991 STAR outputs from RNA-seq of 84 pancreatic neuroendocrine neoplasms, 10 normal islet samples and 4 cell line samples. Illumina HiSeq 2500 98
EGAD00001006992 BWA outputs from whole-exome sequencing of 35 pancreatic neuroendocrine neoplasms. Illumina HiSeq 2500 35
EGAD00001007006 Tumor exomes for 15 DLBCL samples with PMBL GE signature, with 6 matching normal exomes and 1 pooled normal exome. 22
EGAD00001007086 Whole genome sequencing for single cells for library A108757B 1644 cells; filetype=bam HiSeq X Five 5
EGAD00001007087 Whole genome sequencing for single cells for library A98299B 991 cells; filetype=bam HiSeq X Five 5
EGAD00001007088 Whole genome sequencing for single cells for library A108759B 1134 cells; filetype=bam HiSeq X Five 5
EGAD00001007089 Whole genome sequencing for single cells for library A108768B 1126 cells; filetype=bam HiSeq X Five 5
EGAD00001007090 Whole genome sequencing for single cells for library A108837A 1435 cells; filetype=bam HiSeq X Five 5
EGAD00001007091 Whole genome sequencing for single cells for library A108846A 1670 cells; filetype=bam HiSeq X Five 5
EGAD00001007092 Whole genome sequencing for single cells for library A108846B 1636 cells; filetype=bam HiSeq X Five 5
EGAD00001007093 Whole genome sequencing for single cells for library A108879A 1567 cells; filetype=bam HiSeq X Five 5
EGAD00001007094 Whole genome sequencing for single cells for library A110632A 1151 cells; filetype=bam HiSeq X Five 5
EGAD00001007095 Whole genome sequencing for single cells for library A110632B 892 cells; filetype=bam HiSeq X Five 5
EGAD00001007096 Whole genome sequencing for single cells for library A118833A 919 cells; filetype=bam HiSeq X Five 5
EGAD00001007097 Whole genome sequencing for single cells for library A118833B 1147 cells; filetype=bam HiSeq X Five 5
EGAD00001007098 Whole genome sequencing for single cells for library A118845B 1209 cells; filetype=bam HiSeq X Five 5
EGAD00001007099 Whole genome sequencing for single cells for library A118869A 1165 cells; filetype=bam HiSeq X Five 5
EGAD00001007100 Whole genome sequencing for single cells for library A118869B 1124 cells; filetype=bam HiSeq X Five 5
EGAD00001007101 Whole genome sequencing for single cells for library A73044B 2085 cells; filetype=bam Illumina HiSeq 2500 5
EGAD00001007102 Whole genome sequencing for single cells for library A73047D 2091 cells; filetype=bam Illumina HiSeq 2500 5
EGAD00001007103 Whole genome sequencing for single cells for library A95626A 1040 cells; filetype=bam HiSeq X Five 5
EGAD00001007104 Whole genome sequencing for single cells for library A95633B 2259 cells; filetype=bam NextSeq 550 7
EGAD00001007105 Whole genome sequencing for single cells for library A95634B 1335 cells; filetype=bam HiSeq X Five 5
EGAD00001007106 Whole genome sequencing for single cells for library A95646A 1071 cells; filetype=bam HiSeq X Five 5
EGAD00001007107 Whole genome sequencing for single cells for library A95653B 1342 cells; filetype=bam HiSeq X Five 5
EGAD00001007108 Whole genome sequencing for single cells for library A95663B 1364 cells; filetype=bam HiSeq X Five 7
EGAD00001007109 Whole genome sequencing for single cells for library A95675A 668 cells; filetype=bam HiSeq X Five 5
EGAD00001007110 Whole genome sequencing for single cells for library A95731B 1307 cells; filetype=bam HiSeq X Five 5
EGAD00001007111 Whole genome sequencing for single cells for library A96115A 1635 cells; filetype=bam HiSeq X Five 7
EGAD00001007112 Whole genome sequencing for single cells for library A96115B 1201 cells; filetype=bam HiSeq X Five 5
EGAD00001007113 Whole genome sequencing for single cells for library A96118A 1193 cells; filetype=bam HiSeq X Five 5
EGAD00001007114 Whole genome sequencing for single cells for library A96130B 1267 cells; filetype=bam HiSeq X Five 5
EGAD00001007115 Whole genome sequencing for single cells for library A96178A 788 cells; filetype=bam HiSeq X Five 5
EGAD00001007116 Whole genome sequencing for single cells for library A96178B 846 cells; filetype=bam HiSeq X Five 5
EGAD00001007117 Whole genome sequencing for single cells for library A96181C 1216 cells; filetype=bam HiSeq X Five 5
EGAD00001007118 Whole genome sequencing for single cells for library A96193B 2410 cells; filetype=bam HiSeq X Five 4
EGAD00001007119 Whole genome sequencing for single cells for library A96225B 959 cells; filetype=bam HiSeq X Five 4
EGAD00001007120 Whole genome sequencing for single cells for library A96225C 1034 cells; filetype=bam HiSeq X Five 4
EGAD00001007121 Whole genome sequencing for single cells for library A96240A 1493 cells; filetype=bam HiSeq X Five 5
EGAD00001007122 Whole genome sequencing for single cells for library A96240B 1683 cells; filetype=bam HiSeq X Five 5
EGAD00001007123 Whole genome sequencing for single cells for library A98172A 898 cells; filetype=bam HiSeq X Five 5
EGAD00001007124 Whole genome sequencing for single cells for library A98256A 1372 cells; filetype=bam HiSeq X Five 5
EGAD00001007125 Whole genome sequencing for single cells for library A98256B 1437 cells; filetype=bam HiSeq X Five 5
EGAD00001007126 Whole genome sequencing for single cells for library A98257B 1286 cells; filetype=bam HiSeq X Five 5
EGAD00001007127 Whole genome sequencing for single cells for library A98258B 1357 cells; filetype=bam HiSeq X Five 5
EGAD00001007128 Whole genome sequencing for single cells for library A98274B 1295 cells; filetype=bam HiSeq X Five 5
EGAD00001007129 Whole genome sequencing for single cells for library A98282A 1198 cells; filetype=bam HiSeq X Five 5
EGAD00001007130 Whole genome sequencing for single cells for library A98283A 1137 cells; filetype=bam HiSeq X Five 5
EGAD00001007131 Whole genome sequencing for single cells for library A98285A 1422 cells; filetype=bam HiSeq X Five 5
EGAD00001007132 Whole genome sequencing for single cells for library A98295B 1381 cells; filetype=bam HiSeq X Five 5
EGAD00001007306 Whole genome sequencing for single cells for library A95646B 507 cells; filetype=bam HiSeq X Five 5
EGAD00001007529 November 2020 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. unspecified 10
EGAD00001007592 Whole genome sequencing for single cells for library A108732A 1139 cells; filetype=bam HiSeq X Five 7
EGAD00001007593 Whole genome sequencing for single cells for library A108735A 714 cells; filetype=bam NextSeq 550 5
EGAD00001007594 Whole genome sequencing for single cells for library A108833B 866 cells; filetype=bam HiSeq X Five 7
EGAD00001007595 Whole genome sequencing for single cells for library A108842A 1477 cells; filetype=bam HiSeq X Five 5
EGAD00001007596 Whole genome sequencing for single cells for library A108851B 1681 cells; filetype=bam HiSeq X Five 5
EGAD00001007597 Whole genome sequencing for single cells for library A108863A 1301 cells; filetype=bam HiSeq X Five 5
EGAD00001007598 Whole genome sequencing for single cells for library A108870A 1795 cells; filetype=bam HiSeq X Five 5
EGAD00001007599 Whole genome sequencing for single cells for library A110618A 1184 cells; filetype=bam HiSeq X Five 5
EGAD00001007600 Whole genome sequencing for single cells for library A110618B 1047 cells; filetype=bam HiSeq X Five 5
EGAD00001007601 Whole genome sequencing for single cells for library A110621A 1137 cells; filetype=bam HiSeq X Five 5
EGAD00001007602 Whole genome sequencing for single cells for library A110673A 1089 cells; filetype=bam HiSeq X Five 5
EGAD00001007603 Whole genome sequencing for single cells for library A110673B 1153 cells; filetype=bam HiSeq X Five 5
EGAD00001007604 Whole genome sequencing for single cells for library A118830A 912 cells; filetype=bam HiSeq X Five 5
EGAD00001007605 Whole genome sequencing for single cells for library A118862A 1070 cells; filetype=bam HiSeq X Five 5
EGAD00001007606 Whole genome sequencing for single cells for library A118862B 1152 cells; filetype=bam HiSeq X Five 5
EGAD00001007607 Whole genome sequencing for single cells for library A95623A 1897 cells; filetype=bam HiSeq X Five 5
EGAD00001007608 Whole genome sequencing for single cells for library A95623B 1363 cells; filetype=bam HiSeq X Five 5
EGAD00001007609 Whole genome sequencing for single cells for library A95668B 1905 cells; filetype=bam HiSeq X Five 5
EGAD00001007610 Whole genome sequencing for single cells for library A95697B 1233 cells; filetype=bam HiSeq X Five 20
EGAD00001007611 Whole genome sequencing for single cells for library A95700A 1172 cells; filetype=bam HiSeq X Five 5
EGAD00001007612 Whole genome sequencing for single cells for library A95703A 740 cells; filetype=bam NextSeq 550 5
EGAD00001007613 Whole genome sequencing for single cells for library A95720A 1467 cells; filetype=bam HiSeq X Five 5
EGAD00001007614 Whole genome sequencing for single cells for library A95730A 739 cells; filetype=bam HiSeq X Five 5
EGAD00001007615 Whole genome sequencing for single cells for library A96114A 798 cells; filetype=bam NextSeq 550 5
EGAD00001007616 Whole genome sequencing for single cells for library A96124B 1241 cells; filetype=bam HiSeq X Five 5
EGAD00001007617 Whole genome sequencing for single cells for library A96155C 1316 cells; filetype=bam HiSeq X Five 5
EGAD00001007618 Whole genome sequencing for single cells for library A96162A 1505 cells; filetype=bam HiSeq X Five 5
EGAD00001007619 Whole genome sequencing for single cells for library A96183B 1191 cells; filetype=bam HiSeq X Five 5
EGAD00001007620 Whole genome sequencing for single cells for library A96190A 1833 cells; filetype=bam HiSeq X Five 5
EGAD00001007621 Whole genome sequencing for single cells for library A96226B 1274 cells; filetype=bam HiSeq X Five 7
EGAD00001007622 Whole genome sequencing for single cells for library A96233A 637 cells; filetype=bam HiSeq X Five 5
EGAD00001007623 Whole genome sequencing for single cells for library A96233B 1601 cells; filetype=bam HiSeq X Five 5
EGAD00001007624 Whole genome sequencing for single cells for library A98168A 1294 cells; filetype=bam HiSeq X Five 5
EGAD00001007625 Whole genome sequencing for single cells for library A98168B 1290 cells; filetype=bam HiSeq X Five 5
EGAD00001007626 Whole genome sequencing for single cells for library A98234A 1240 cells; filetype=bam HiSeq X Five 5
EGAD00001007627 Whole genome sequencing for single cells for library A98234B 1600 cells; filetype=bam HiSeq X Five 5
EGAD00001007628 Whole genome sequencing for single cells for library A98244A 1271 cells; filetype=bam HiSeq X Five 7
EGAD00001007629 Whole genome sequencing for single cells for library A98253A 1250 cells; filetype=bam HiSeq X Five 5
EGAD00001007630 Whole genome sequencing for single cells for library A98253B 1388 cells; filetype=bam HiSeq X Five 5
EGAD00001007631 Whole genome sequencing for single cells for library A98254A 1490 cells; filetype=bam HiSeq X Five 7
EGAD00001007632 Whole genome sequencing for single cells for library A98255B 1394 cells; filetype=bam HiSeq X Five 5
EGAD00001007633 Whole genome sequencing for single cells for library A98271A 1190 cells; filetype=bam HiSeq X Five 5
EGAD00001007634 Whole genome sequencing for single cells for library A98289A 1066 cells; filetype=bam HiSeq X Five 5
EGAD00001007635 Whole genome sequencing for single cells for library A98290B 869 cells; filetype=bam HiSeq X Five 5
EGAD00001007636 Whole genome sequencing for single cells for library A98304A 1560 cells; filetype=bam HiSeq X Five 7
EGAD00001007637 Whole genome sequencing for single cells for library A98305A 986 cells; filetype=bam HiSeq X Five 5
EGAD00001007640 Whole genome sequencing for single cells for library A96120A 1143 cells; filetype=bam HiSeq X Five 11
EGAD00001007641 Whole genome sequencing for single cells for library A98172B 941 cells; filetype=bam HiSeq X Five 5
EGAD00001007756 OV2295-052021 dataset Illumina HiSeq 2000 1
EGAD00001007812 We analyzed 34 AGCTs (19 primary and 15 recurrent) and the KGN cell line by RNA-Seq. Our cohort comprised of 3 AGCTs WT for FOXL2, 28 heterozygous and 3 homo/hemizygous for the pathogenic variant. Fresh-frozen AGCTs were selected from OVCARE’s Gynecological Tissue Bank in Vancouver, Canada for bulk RNA-seq. RNA was extracted from frozen tissue and sections adjacent to the scrolls submitted for RNA-seq were stained with hematoxylin and eosin (H&E) to evaluate tumour cell purity. Cases with >80% tumour cell purity were selected for sequencing with the majority of cases (29 of 34 patients) containing >90% tumour cells. Ribodepleted RNA libraries were constructed and paired-end sequencing (125 base pair reads) was performed. Illumina HiSeq 2500 35
EGAD00001007919 February 2021 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. unspecified 5
EGAD00001007920 This paper describes the work by Akbari V,. et al. on detection of allele specific methylation using oxford nanopore sequencing data. They have developed set of tools, SNVoter and NanoMethPhase, and workflow which enable the detection of allele specific methylation even in samples with sparse coverage of nanopore sequencing data. PromethION 1
EGAD00001007935 Whole-exome sequencing (~250X coverage) of primary GBM tumours and matched patient-derived organoids and normal blood. Samples from two spatially distinct regions of seven tumours from five patients (five primary, two recurrent). Illumina HiSeq 2500 29
EGAD00001007936 Single-cell RNA-seq of primary GBM tumours and matched patient-derived organoids and gliomasphere lines. Obtained using the 10X Genomics single-cell 3' expression solution (v2 chemistry). Primary samples and PDOs from 12 tumours from 10 patients (10 primary, two recurrent), and gliomasphere lines from a subset of five tumours. Samples were obtained from two spatially distinct regions of each tumour. Illumina HiSeq 2500 99
EGAD00001007937 Single-cell whole-genome sequencing of primary GBM tumours and matched patient-derived organoids. Obtained using the 10X Genomics single-cell CNV solution. Samples from two spatially distinct regions of five tumours from three patients (three primary, two recurrent). HiSeq X Ten 16
EGAD00001008012 Genome and transcriptome sequence data from a poorly differentiated chordoma of C1-C2 spine patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001008013 Genome and transcriptome sequence data from an unspecified tissue chordoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001008100 May 2021 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. unspecified 17
EGAD00001008101 August 2021 data update (fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. unspecified 13
EGAD00001008218 Whole genome sequencing for single cells for library A96228B 1125 samples; filetype=bam HiSeq X Five 6
EGAD00001008219 Whole genome sequencing for single cells for library A90679 1034 samples; filetype=bam Illumina HiSeq 2500 4
EGAD00001008220 Whole genome sequencing for single cells for library A95618A 876 samples; filetype=bam HiSeq X Five 9
EGAD00001008221 Whole genome sequencing for single cells for library A95628B 1335 samples; filetype=bam HiSeq X Five 5
EGAD00001008222 Whole genome sequencing for single cells for library A95632D 644 samples; filetype=bam Illumina HiSeq 2500 5
EGAD00001008223 Whole genome sequencing for single cells for library A95635B 593 samples; filetype=bam Illumina HiSeq 2500 4
EGAD00001008224 Whole genome sequencing for single cells for library A95635D 367 samples; filetype=bam Illumina HiSeq 2500 5
EGAD00001008225 Whole genome sequencing for single cells for library A95654A 901 samples; filetype=bam HiSeq X Five 5
EGAD00001008226 Whole genome sequencing for single cells for library A95662A 637 samples; filetype=bam Illumina HiSeq 2500 5
EGAD00001008227 Whole genome sequencing for single cells for library A95664B 630 samples; filetype=bam Illumina HiSeq 2500 5
EGAD00001008228 Whole genome sequencing for single cells for library A95707A 1359 samples; filetype=bam HiSeq X Five 9
EGAD00001008229 Whole genome sequencing for single cells for library A95724A 503 samples; filetype=bam NextSeq 550 5
EGAD00001008230 Whole genome sequencing for single cells for library A95724B 581 samples; filetype=bam NextSeq 550 5
EGAD00001008231 Whole genome sequencing for single cells for library A95732B 655 samples; filetype=bam HiSeq X Five 5
EGAD00001008232 Whole genome sequencing for single cells for library A96145A 642 samples; filetype=bam HiSeq X Five 9
EGAD00001008233 Whole genome sequencing for single cells for library A96146A 1195 samples; filetype=bam HiSeq X Five 5
EGAD00001008234 Whole genome sequencing for single cells for library A96149A 751 samples; filetype=bam HiSeq X Five 5
EGAD00001008235 Whole genome sequencing for single cells for library A96149B 1792 samples; filetype=bam HiSeq X Five 5
EGAD00001008236 Whole genome sequencing for single cells for library A96155B 1028 samples; filetype=bam HiSeq X Five 5
EGAD00001008237 Whole genome sequencing for single cells for library A96157C 938 samples; filetype=bam HiSeq X Five 7
EGAD00001008238 Whole genome sequencing for single cells for library A96162B 1316 samples; filetype=bam HiSeq X Five 7
EGAD00001008239 Whole genome sequencing for single cells for library A96165A 779 samples; filetype=bam HiSeq X Five 7
EGAD00001008240 Whole genome sequencing for single cells for library A96172A 1476 samples; filetype=bam HiSeq X Five 7
EGAD00001008241 Whole genome sequencing for single cells for library A96172B 1694 samples; filetype=bam HiSeq X Five 5
EGAD00001008242 Whole genome sequencing for single cells for library A96174B 1447 samples; filetype=bam HiSeq X Five 7
EGAD00001008243 Whole genome sequencing for single cells for library A96175C 1473 samples; filetype=bam HiSeq X Five 5
EGAD00001008244 Whole genome sequencing for single cells for library A96177B 683 samples; filetype=bam HiSeq X Five 9
EGAD00001008245 Whole genome sequencing for single cells for library A96179B 1396 samples; filetype=bam HiSeq X Five 7
EGAD00001008246 Whole genome sequencing for single cells for library A96180B 1189 samples; filetype=bam HiSeq X Five 5
EGAD00001008247 Whole genome sequencing for single cells for library A96183C 1036 samples; filetype=bam HiSeq X Five 5
EGAD00001008248 Whole genome sequencing for single cells for library A96184A 1733 samples; filetype=bam HiSeq X Five 7
EGAD00001008249 Whole genome sequencing for single cells for library A96186A 850 samples; filetype=bam HiSeq X Five 5
EGAD00001008250 Whole genome sequencing for single cells for library A96186C 525 samples; filetype=bam HiSeq X Five 5
EGAD00001008251 Whole genome sequencing for single cells for library A96199B 1170 samples; filetype=bam HiSeq X Five 5
EGAD00001008252 Whole genome sequencing for single cells for library A96201A 536 samples; filetype=bam HiSeq X Five 5
EGAD00001008253 Whole genome sequencing for single cells for library A96205A 1907 samples; filetype=bam HiSeq X Five 7
EGAD00001008254 Whole genome sequencing for single cells for library A96210C 1191 samples; filetype=bam HiSeq X Five 5
EGAD00001008255 Whole genome sequencing for single cells for library A96211C 1397 samples; filetype=bam HiSeq X Five 5
EGAD00001008256 Whole genome sequencing for single cells for library A96215A 1312 samples; filetype=bam HiSeq X Five 5
EGAD00001008257 Whole genome sequencing for single cells for library A96216A 1001 samples; filetype=bam HiSeq X Five 9
EGAD00001008258 Whole genome sequencing for single cells for library A96220B 1267 samples; filetype=bam HiSeq X Five 5
EGAD00001008259 Whole genome sequencing for single cells for library A96244A 1374 samples; filetype=bam HiSeq X Five 5
EGAD00001008260 Whole genome sequencing for single cells for library A98176A 1003 samples; filetype=bam HiSeq X Five 5
EGAD00001008261 Whole genome sequencing for single cells for library A98176B 1389 samples; filetype=bam HiSeq X Five 5
EGAD00001008262 Whole genome sequencing for single cells for library A98284A 1265 samples; filetype=bam HiSeq X Five 4
EGAD00001008263 Whole genome sequencing for single cells for library A98284B 1582 samples; filetype=bam HiSeq X Five 2
EGAD00001008264 Whole genome sequencing for single cells for library A98289B 1032 samples; filetype=bam HiSeq X Five 5
EGAD00001008265 Whole genome sequencing for single cells for library A98293B 703 samples; filetype=bam HiSeq X Five 5
EGAD00001008266 Whole genome sequencing for single cells for library A98294A 994 samples; filetype=bam HiSeq X Five 5
EGAD00001008270 This dataset contains raw count data (10X CellRanger) for 28 Hodgkin lymphoma samples and 5 reactive lymph nodes, and merged data from all samples (RData object) including cell cluster assignments. 34
EGAD00001008431 Single-cell RNA-seq of first-, second-, and third-generation patient-derived organoids. Obtained using the 10X Genomics single-cell 3' expression solution (v3 chemistry). First- and second-generation PDOs from one patient and first-, second-, and third-generation PDOs from three additional patients. Illumina NovaSeq 6000 11
EGAD00001008516 WGS and RNA-Seq data from a GBM patient PT-BM8772 Illumina HiSeq 2500 1
EGAD00001008517 WGS and RNA-Seq data from a GBM patient PT-CM3220 Illumina HiSeq 2000,Illumina HiSeq 2500 2
EGAD00001008518 WGS and RNA-Seq data from a GBM patient PT-DM9089 Illumina HiSeq 2000,Illumina HiSeq 2500 2
EGAD00001008519 WGS and RNA-Seq data from a GBM patient PT-GE7528 Illumina HiSeq 2000 1
EGAD00001008520 WGS and RNA-Seq data from a GBM patient PT-GI2070 Illumina HiSeq 2000 1
EGAD00001008521 WGS and RNA-Seq data from a GBM patient PT-JR9883 Illumina HiSeq 2000 1
EGAD00001008522 WGS and RNA-Seq data from a GBM patient PT-LC6372 Illumina HiSeq 2500 1
EGAD00001008523 WGS and RNA-Seq data from a GBM patient PT-ML9537 Illumina HiSeq 2500 1
EGAD00001008524 WGS data from a GBM patient PT-MS8478 0
EGAD00001008525 WGS and RNA-Seq data from a GBM patient PT-PR5617 Illumina HiSeq 2000,Illumina HiSeq 2500 2
EGAD00001008526 WGS and RNA-Seq data from a GBM patient PT-PV2594 Illumina HiSeq 2000,Illumina HiSeq 2500 5
EGAD00001008527 WGS and RNA-Seq data from a GBM patient PT-RV2286 Illumina HiSeq 2500 1
EGAD00001008528 WGS data from a GBM patient PT-SB3465 0
EGAD00001008529 WGS and RNA-Seq data from a GBM patient PT-SJ5453 Illumina HiSeq 2000,Illumina HiSeq 2500 3
EGAD00001008530 WGS and RNA-Seq data from a GBM patient PT-SS3647 Illumina HiSeq 2000,Illumina HiSeq 2500 3
EGAD00001008531 WGS and RNA-Seq data from a GBM patient PT-WR7927 Illumina HiSeq 2500 1
EGAD00001008532 WGS and RNA-Seq data from a GBM patient PT-WT4796 Illumina HiSeq 2000 1
EGAD00001008690 Long-read genome sequencing performed on the Oxford Nanopore Technologies' PromethION to resolve variants underlying breast cancer susceptibility in sixteen individuals with pathogenic germline SVs in BRCA1, BRCA2, CHEK2 or PALB2. PromethION 16
EGAD00001008756 41 WGS DNA sequences from: Phase I trial of CX-5461, a first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies (CCTG IND.231) Illumina HiSeq X 56
EGAD00001009111 10x Genomics Single Cell Gene Expression for Telomerase immortalized breast epithelium cell line 184-hTERT-22 L9 112.109 Illumina HiSeq 2500 1
EGAD00001009112 10x Genomics Single Cell Gene Expression for Telomerase immortalized breast epithelium cell line 184-hTERT-22 L9 116.126 Illumina HiSeq 2500 1
EGAD00001009113 10x Genomics Single Cell Gene Expression for Telomerase immortalized breast epithelium cell line 184-hTERT-22 L9 83.86 Illumina HiSeq 2500 1
EGAD00001009114 10x Genomics Single Cell Gene Expression for Telomerase immortalized breast epithelium cell line 184-hTert L9 116.66 Illumina HiSeq 2500 1
EGAD00001009115 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 4 BGISEQ-500 1
EGAD00001009116 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 6 Illumina HiSeq 2500 1
EGAD00001009117 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA604 passage 6 Illumina HiSeq 2500 1
EGAD00001009118 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA604 passage 8 Illumina HiSeq 2500 1
EGAD00001009119 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA604 passage 7 NextSeq 500 1
EGAD00001009120 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA609 passage 6 Illumina HiSeq 2500 1
EGAD00001009121 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1049 passage 1 NextSeq 500 1
EGAD00001009122 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1052 passage 1 NextSeq 500 1
EGAD00001009123 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1053 passage 1 NextSeq 500 1
EGAD00001009124 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1051 passage 1 NextSeq 500 1
EGAD00001009125 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1050 passage 1 NextSeq 500 1
EGAD00001009126 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1050 passage 1 NextSeq 500 1
EGAD00001009127 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1052 passage 1 NextSeq 500 1
EGAD00001009128 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1053 passage 1 Illumina HiSeq 2500 1
EGAD00001009129 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1093 passage 1 NextSeq 500 1
EGAD00001009130 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1091 passage 1 NextSeq 500 1
EGAD00001009131 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1053 passage 1 NextSeq 500 1
EGAD00001009132 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1096 passage 1 NextSeq 500 1
EGAD00001009133 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1051 passage 1 HiSeq X Ten 1
EGAD00001009134 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1052 passage 1 HiSeq X Ten 1
EGAD00001009135 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1181 passage 1 Illumina HiSeq 2500 1
EGAD00001009136 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1096 passage 1 Illumina HiSeq 2500 1
EGAD00001009137 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1096 passage 1 Illumina HiSeq 2500 1
EGAD00001009138 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1162 passage 1 Illumina HiSeq 2500 1
EGAD00001009139 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient SA1096 NextSeq 500 1
EGAD00001009140 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1049 passage 1 NextSeq 500 1
EGAD00001009141 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1050 passage 1 Illumina HiSeq 2500 1
EGAD00001009142 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA605 passage 3 NextSeq 500 1
EGAD00001009143 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma cell line OV2295 HiSeq X Ten 1
EGAD00001009144 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma cell line OV2295(R2) HiSeq X Ten 1
EGAD00001009145 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient SA1184 NextSeq 500 1
EGAD00001009146 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma patient-derived xenograft SA1047 passage 1 HiSeq X Ten 1
EGAD00001009147 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 4 Illumina HiSeq 2500 1
EGAD00001009148 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 8 NextSeq 500 1
EGAD00001009149 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 6 BGISEQ-500 1
EGAD00001009150 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 6 Illumina HiSeq 2500 1
EGAD00001009151 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 7 HiSeq X Ten 1
EGAD00001009152 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 4 BGISEQ-500 1
EGAD00001009153 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 5 Illumina HiSeq 2500 1
EGAD00001009154 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 6 Illumina HiSeq 2500 1
EGAD00001009155 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 5 HiSeq X Ten 1
EGAD00001009156 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 5 HiSeq X Ten 1
EGAD00001009157 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 9 Illumina HiSeq 2500 1
EGAD00001009158 10x Genomics Single Cell Gene Expression for High grade serous ovarian carcinoma cell line TOV2295(R) HiSeq X Ten 1
EGAD00001009159 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA604 passage 9 NextSeq 500 1
EGAD00001009160 10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA610 passage 3 HiSeq X Ten 1
EGAD00001009177 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA218 Illumina HiSeq 2500 1
EGAD00001009178 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA219 Illumina HiSeq 2500 1
EGAD00001009179 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA272 Illumina HiSeq 2500 1
EGAD00001009180 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA274 Illumina HiSeq 2500 1
EGAD00001009181 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA275 Illumina HiSeq 2500 1
EGAD00001009182 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA276 Illumina HiSeq 2500 1
EGAD00001009183 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA279 Illumina HiSeq 2500 1
EGAD00001009184 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA283 Illumina HiSeq 2500 1
EGAD00001009185 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA287 Illumina HiSeq 2500 1
EGAD00001009186 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA394 Illumina HiSeq 2500 1
EGAD00001009187 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA395 Illumina HiSeq 2500 1
EGAD00001009188 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA398 Illumina HiSeq 2500 1
EGAD00001009189 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA402 Illumina HiSeq 2500 1
EGAD00001009190 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA404 Illumina HiSeq 2500 1
EGAD00001009191 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA530 Illumina HiSeq 2000 1
EGAD00001009192 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA585 Illumina HiSeq 2500 1
EGAD00001009193 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA586 Illumina HiSeq 2500 1
EGAD00001009194 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA588 Illumina HiSeq 2500 1
EGAD00001009195 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA589 Illumina HiSeq 2500 1
EGAD00001009196 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA590 Illumina HiSeq 2500 1
EGAD00001009197 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA591 Illumina HiSeq 2500 1
EGAD00001009198 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA592 Illumina HiSeq 2500 1
EGAD00001009199 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA593 Illumina HiSeq 2500 1
EGAD00001009200 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA595 Illumina HiSeq 2500 1
EGAD00001009201 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA596 Illumina HiSeq 2500 1
EGAD00001009202 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA598 Illumina HiSeq 2500 1
EGAD00001009203 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA599 Illumina HiSeq 2500 1
EGAD00001009204 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA600 Illumina HiSeq 2500 1
EGAD00001009205 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA601 Illumina HiSeq 2500 1
EGAD00001009206 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA654 Illumina HiSeq 2500 1
EGAD00001009207 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA655 Illumina HiSeq 2500 1
EGAD00001009208 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA665 Illumina HiSeq 2500 1
EGAD00001009209 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA666 Illumina HiSeq 2500 1
EGAD00001009210 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA667 Illumina HiSeq 2500 1
EGAD00001009211 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA668 Illumina HiSeq 2500 1
EGAD00001009212 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA669 Illumina HiSeq 2500 1
EGAD00001009213 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA671 Illumina HiSeq 2500 1
EGAD00001009214 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA672 Illumina HiSeq 2500 1
EGAD00001009215 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA535 Illumina HiSeq 2000 1
EGAD00001009216 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1035 Illumina HiSeq X 1
EGAD00001009217 Whole genome sequencing of normal sample for triple negative breast cancer patient SA604 Illumina HiSeq 2500 1
EGAD00001009218 Whole genome sequencing of normal sample for triple negative breast cancer patient SA605 Illumina HiSeq 2500 1
EGAD00001009219 Whole genome sequencing of normal sample for triple negative breast cancer patient SA609 Illumina HiSeq 2500 1
EGAD00001009220 Whole genome sequencing of normal sample for triple negative breast cancer patient SA218 Illumina HiSeq 2500 1
EGAD00001009221 Whole genome sequencing of normal sample for triple negative breast cancer patient SA219 Illumina HiSeq 2500 1
EGAD00001009222 Whole genome sequencing of normal sample for triple negative breast cancer patient SA272 Illumina HiSeq 2500 1
EGAD00001009223 Whole genome sequencing of normal sample for triple negative breast cancer patient SA274 Illumina HiSeq 2500 1
EGAD00001009224 Whole genome sequencing of normal sample for triple negative breast cancer patient SA275 Illumina HiSeq 2500 1
EGAD00001009225 Whole genome sequencing of normal sample for triple negative breast cancer patient SA276 Illumina HiSeq 2500 1
EGAD00001009226 Whole genome sequencing of normal sample for triple negative breast cancer patient SA279 Illumina HiSeq 2500 1
EGAD00001009227 Whole genome sequencing of normal sample for triple negative breast cancer patient SA283 Illumina HiSeq 2500 1
EGAD00001009228 Whole genome sequencing of normal sample for triple negative breast cancer patient SA287 Illumina HiSeq 2500 1
EGAD00001009229 Whole genome sequencing of normal sample for triple negative breast cancer patient SA394 Illumina HiSeq 2500 1
EGAD00001009230 Whole genome sequencing of normal sample for triple negative breast cancer patient SA395 Illumina HiSeq 2500 1
EGAD00001009231 Whole genome sequencing of normal sample for triple negative breast cancer patient SA398 Illumina HiSeq 2500 1
EGAD00001009232 Whole genome sequencing of normal sample for triple negative breast cancer patient SA402 Illumina HiSeq 2500 1
EGAD00001009233 Whole genome sequencing of normal sample for triple negative breast cancer patient SA404 Illumina HiSeq 2500 1
EGAD00001009234 Whole genome sequencing of normal sample for triple negative breast cancer patient SA530 Illumina HiSeq 2500 1
EGAD00001009235 Whole genome sequencing of normal sample for triple negative breast cancer patient SA535 Illumina HiSeq 2000 1
EGAD00001009236 Whole genome sequencing of normal sample for triple negative breast cancer patient SA585 Illumina HiSeq 2500 1
EGAD00001009237 Whole genome sequencing of normal sample for triple negative breast cancer patient SA586 Illumina HiSeq 2500 1
EGAD00001009238 Whole genome sequencing of normal sample for triple negative breast cancer patient SA588 Illumina HiSeq 2500 1
EGAD00001009239 Whole genome sequencing of normal sample for triple negative breast cancer patient SA589 Illumina HiSeq 2500 1
EGAD00001009240 Whole genome sequencing of normal sample for triple negative breast cancer patient SA590 Illumina HiSeq 2500 1
EGAD00001009241 Whole genome sequencing of normal sample for triple negative breast cancer patient SA591 Illumina HiSeq 2500 1
EGAD00001009242 Whole genome sequencing of normal sample for triple negative breast cancer patient SA592 Illumina HiSeq 2500 1
EGAD00001009243 Whole genome sequencing of normal sample for triple negative breast cancer patient SA593 Illumina HiSeq 2500 1
EGAD00001009244 Whole genome sequencing of normal sample for triple negative breast cancer patient SA595 Illumina HiSeq 2500 1
EGAD00001009245 Whole genome sequencing of normal sample for triple negative breast cancer patient SA596 Illumina HiSeq 2500 1
EGAD00001009246 Whole genome sequencing of normal sample for triple negative breast cancer patient SA598 Illumina HiSeq 2500 1
EGAD00001009247 Whole genome sequencing of normal sample for triple negative breast cancer patient SA599 Illumina HiSeq 2500 1
EGAD00001009248 Whole genome sequencing of normal sample for triple negative breast cancer patient SA600 Illumina HiSeq 2500 1
EGAD00001009249 Whole genome sequencing of normal sample for triple negative breast cancer patient SA601 Illumina HiSeq 2500 1
EGAD00001009250 Whole genome sequencing of normal sample for triple negative breast cancer patient SA654 Illumina HiSeq 2500 1
EGAD00001009251 Whole genome sequencing of normal sample for triple negative breast cancer patient SA655 Illumina HiSeq 2500 1
EGAD00001009252 Whole genome sequencing of normal sample for triple negative breast cancer patient SA665 Illumina HiSeq 2500 1
EGAD00001009253 Whole genome sequencing of normal sample for triple negative breast cancer patient SA667 Illumina HiSeq 2500 1
EGAD00001009254 Whole genome sequencing of normal sample for triple negative breast cancer patient SA668 Illumina HiSeq 2500 1
EGAD00001009255 Whole genome sequencing of normal sample for triple negative breast cancer patient SA669 Illumina HiSeq 2500 1
EGAD00001009256 Whole genome sequencing of normal sample for triple negative breast cancer patient SA671 Illumina HiSeq 2500 1
EGAD00001009257 Whole genome sequencing of normal sample for triple negative breast cancer patient SA672 Illumina HiSeq 2500 1
EGAD00001009258 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1035 Illumina HiSeq X 1
EGAD00001009259 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA994 Illumina HiSeq X 1
EGAD00001009260 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA604 Illumina HiSeq 2500 1
EGAD00001009261 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA605 Illumina HiSeq 2500 1
EGAD00001009262 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA609 Illumina HiSeq 2500 1
EGAD00001009316 Single Cell Genome Sequence for Triple negative breast cancer patient-derived xenograft SA609 passage 3 on DLP+ library A95618B NextSeq 550 15
EGAD00001009319 Single Cell Genome Sequence for triple negative breast cancer patient SA1162SB on DLP+ library A95628A HiSeq X Ten 3
EGAD00001009320 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1051D passage 1 on DLP+ library A95629B HiSeq X Ten 3
EGAD00001009321 Single Cell Genome Sequence for immortalized breast epithelium - BRCA1-/- Tp53-/- cell line 184-hTERT-22 L9 83.86 on DLP+ library A95632A Illumina HiSeq 2500 7
EGAD00001009322 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA609 passage 6 on DLP+ library A95632C NextSeq 550 8
EGAD00001009323 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1091A passage 1 on DLP+ library A95634A HiSeq X Ten 3
EGAD00001009324 Single Cell Genome Sequence for immortalized breast epithelium - BRCA2-/-; Tp53-/- cell line 184-hTERT-22 L9 116.126 on DLP+ library A95635A Illumina HiSeq 2500 4
EGAD00001009325 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1052J passage 1 on DLP+ library A95650A HiSeq X Ten 3
EGAD00001009326 Single Cell Genome Sequence for immortalized breast epithelium BRCA2+/- Tp53-/- cell line 184-hTert L9 116.66 on DLP+ library A95652A HiSeq X Ten 2
EGAD00001009327 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1049A passage 1 on DLP+ library A95652B HiSeq X Ten 3
EGAD00001009340 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA673 Illumina HiSeq 2500 1
EGAD00001009341 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA674 Illumina HiSeq 2500 1
EGAD00001009342 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA675 Illumina HiSeq 2500 1
EGAD00001009343 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA676 Illumina HiSeq 2500 1
EGAD00001009344 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA677 Illumina HiSeq 2500 1
EGAD00001009345 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA678 Illumina HiSeq 2500 1
EGAD00001009346 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA679 Illumina HiSeq 2500 1
EGAD00001009347 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA680 Illumina HiSeq 2500 1
EGAD00001009348 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA681 Illumina HiSeq 2500 1
EGAD00001009349 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA682 Illumina HiSeq 2500 1
EGAD00001009350 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA683 Illumina HiSeq 2500 1
EGAD00001009351 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA221 Illumina HiSeq 2000 1
EGAD00001009352 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA238 Illumina HiSeq 2000 1
EGAD00001009353 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA239 Illumina HiSeq 2000 1
EGAD00001009354 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA300 Illumina HiSeq 2000 1
EGAD00001009355 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA423 Illumina HiSeq 2000 1
EGAD00001009356 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA425 Illumina HiSeq 2000 1
EGAD00001009357 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA495 Illumina HiSeq 2000 1
EGAD00001009358 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA286 Illumina HiSeq 2000 1
EGAD00001009359 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA289 Illumina HiSeq 2000 1
EGAD00001009360 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA291 Illumina HiSeq 2000 1
EGAD00001009361 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA280 Illumina HiSeq 2000 1
EGAD00001009362 Whole genome sequencing of normal sample for triple negative breast cancer patient SA221 Illumina HiSeq 2000 1
EGAD00001009363 Whole genome sequencing of normal sample for triple negative breast cancer patient SA238 Illumina HiSeq 2000 1
EGAD00001009364 Whole genome sequencing of normal sample for triple negative breast cancer patient SA239 Illumina HiSeq 2000 1
EGAD00001009365 Whole genome sequencing of normal sample for triple negative breast cancer patient SA280 Illumina HiSeq 2000 1
EGAD00001009366 Whole genome sequencing of normal sample for triple negative breast cancer patient SA286 Illumina HiSeq 2000 1
EGAD00001009367 Whole genome sequencing of normal sample for triple negative breast cancer patient SA289 Illumina HiSeq 2000 1
EGAD00001009368 Whole genome sequencing of normal sample for triple negative breast cancer patient SA291 Illumina HiSeq 2000 1
EGAD00001009369 Whole genome sequencing of normal sample for triple negative breast cancer patient SA300 Illumina HiSeq 2000 1
EGAD00001009370 Whole genome sequencing of normal sample for triple negative breast cancer patient SA423 Illumina HiSeq 2000 1
EGAD00001009371 Whole genome sequencing of normal sample for triple negative breast cancer patient SA425 Illumina HiSeq 2000 1
EGAD00001009372 Whole genome sequencing of normal sample for triple negative breast cancer patient SA495 Illumina HiSeq 2000 1
EGAD00001009373 Whole genome sequencing of normal sample for triple negative breast cancer patient SA673 Illumina HiSeq 2500 1
EGAD00001009374 Whole genome sequencing of normal sample for triple negative breast cancer patient SA674 Illumina HiSeq 2500 1
EGAD00001009375 Whole genome sequencing of normal sample for triple negative breast cancer patient SA675 Illumina HiSeq 2500 1
EGAD00001009376 Whole genome sequencing of normal sample for triple negative breast cancer patient SA676 Illumina HiSeq 2500 1
EGAD00001009377 Whole genome sequencing of normal sample for triple negative breast cancer patient SA677 Illumina HiSeq 2500 1
EGAD00001009378 Whole genome sequencing of normal sample for triple negative breast cancer patient SA678 Illumina HiSeq 2500 1
EGAD00001009379 Whole genome sequencing of normal sample for triple negative breast cancer patient SA679 Illumina HiSeq 2500 1
EGAD00001009380 Whole genome sequencing of normal sample for triple negative breast cancer patient SA680 Illumina HiSeq 2500 1
EGAD00001009381 Whole genome sequencing of normal sample for triple negative breast cancer patient SA681 Illumina HiSeq 2500 1
EGAD00001009382 Whole genome sequencing of normal sample for triple negative breast cancer patient SA682 Illumina HiSeq 2500 1
EGAD00001009383 Whole genome sequencing of normal sample for triple negative breast cancer patient SA683 Illumina HiSeq 2500 1
EGAD00001009428 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1181A passage 1 on DLP library A108765A HiSeq X Ten 3
EGAD00001009429 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1182E passage 1 on DLP+ library A108847B HiSeq X Ten 4
EGAD00001009430 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA610 passage 3 on DLP+ library A110660A HiSeq X Ten 4
EGAD00001009431 Single Cell Genome Sequence for Immortalized breast epithelium BRCA2+/- Tp53-/- cell line 184-hTert L9 116.66 cell line SA1188 on DLP+ library A118357B HiSeq X Ten 3
EGAD00001009432 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA605 passage 3 on DLP+ library A118368B HiSeq X Ten 4
EGAD00001009433 Single Cell Genome Sequence for Telomerase immortalized breast epithelium cell line 184-hTERT 85.14 p20 cell line AT135 on DLP+ library A118389B NextSeq 2000 4
EGAD00001009434 Single Cell Genome Sequence for Immortalized breast epithelium BRCA2+/- Tp53-/- cell line 184-hTert L9 116.66 cell line SA1188 on DLP+ library A118425B HiSeq X Ten 3
EGAD00001009435 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1050B passage 1, patient-derived xenograft SA1050E passage 1 on DLP+ library A118782A HiSeq X Ten 6
EGAD00001009436 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1050B passage 1, patient-derived xenograft SA1050E passage 1 on DLP+ library A118784A HiSeq X Ten 6
EGAD00001009437 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA610 passage 3, patient-derived xenograft SA1096C passage 1 on DLP+ library A118790A HiSeq X Ten 6
EGAD00001009438 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1184D passage 1 on DLP+ library A118797B HiSeq X Ten 4
EGAD00001009439 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1162B passage 1, patient-derived xenograft SA1096B passage 1 on DLP+ library A118804A HiSeq X Ten 6
EGAD00001009440 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1096B passage 1 on DLP+ library A118808A HiSeq X Ten 4
EGAD00001009441 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1096C passage 1 on DLP+ library A118808B HiSeq X Ten 4
EGAD00001009442 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1180C passage 1 on DLP+ library A118812B HiSeq X Ten 4
EGAD00001009443 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1162B passage 1 on DLP+ library A118814B HiSeq X Ten 4
EGAD00001009444 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1180C passage 1 on DLP+ library A118816A HiSeq X Ten 4
EGAD00001009445 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1184D passage 1 on DLP+ library A118857B HiSeq X Ten 4
EGAD00001009446 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1053F passage 1 on DLP+ library A95663A HiSeq X Ten 3
EGAD00001009447 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient SA1162SA on DLP+ library A95668A HiSeq X Ten 3
EGAD00001009448 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 5 on DLP+ library A95670A NextSeq 550 3
EGAD00001009449 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 6 on DLP+ library A95670B NextSeq 550 3
EGAD00001009450 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1096A passage 1 on DLP+ library A95717A HiSeq X Ten 3
EGAD00001009451 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 6 on DLP+ library A95722A HiSeq X Ten 7
EGAD00001009452 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 2 on DLP+ library A96109A HiSeq X Ten 5
EGAD00001009453 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1049A passage on DLP+ library A96113A NextSeq 550 6
EGAD00001009454 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA609 passage 8 on DLP+ library A96130A HiSeq X Ten 3
EGAD00001009455 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient SA1162SA on DLP+ library A96142B HiSeq X Ten 3
EGAD00001009456 Single Cell Genome Sequence for triple negative breast cancer patient SA1135, patient SA1162SA on DLP+ library A96154A HiSeq X Ten 5
EGAD00001009457 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 8 on DLP+ library A96161A HiSeq X Ten 5
EGAD00001009458 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 2, patient-derived xenograft SA611 passage 3 on DLP+ library A96171A HiSeq X Ten 7
EGAD00001009459 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 15 on DLP+ library A96173A HiSeq X Ten 7
EGAD00001009460 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 11 on DLP+ library A96174A HiSeq X Ten 3
EGAD00001009461 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 7 on DLP+ library A96175A HiSeq X Ten 3
EGAD00001009462 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 6 on DLP+ library A96177C HiSeq X Ten 3
EGAD00001009463 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 6 on DLP+ library A96180A HiSeq X Ten 3
EGAD00001009464 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 11, patient-derived xenograft SA609 passage 7 on DLP+ library A96187A HiSeq X Ten 10
EGAD00001009465 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1049C passage 1 on DLP+ library A96189A HiSeq X Ten 3
EGAD00001009466 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1051A passage 1 on DLP+ library A96190B HiSeq X Ten 3
EGAD00001009467 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1093C passage 1, patient SA1147 on DLP+ library A96192A HiSeq X Ten 5
EGAD00001009468 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1053B passage 1 on DLP+ library A96194A HiSeq X Ten 3
EGAD00001009469 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1053E passage 1 on DLP+ library A96194B HiSeq X Ten 3
EGAD00001009470 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1052D passage 1 on DLP+ library A96200B HiSeq X Ten 3
EGAD00001009471 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1049A passage 1 on DLP+ library A96205B HiSeq X Ten 0
EGAD00001009472 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1050F passage 1 on DLP+ library A96206B HiSeq X Ten 3
EGAD00001009473 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1051A passage 1 on DLP+ library A96207A HiSeq X Ten 3
EGAD00001009474 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1052B passage 1 on DLP+ library A96207B HiSeq X Ten 3
EGAD00001009475 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient SA1047B on DLP+ library A96210B HiSeq X Ten 3
EGAD00001009476 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 7 on DLP+ library A96212B HiSeq X Ten 5
EGAD00001009477 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 6, cell line SA1090 on DLP+ library A96213A HiSeq X Ten 5
EGAD00001009478 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient SA1105, patient SA1103, patient SA1106, patient SA1102, patient SA1104 on DLP+ library A96222A NextSeq 550 11
EGAD00001009479 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA919 passage 7, patient-derived xenograft SA1050A passage 1 on DLP+ library A98181A HiSeq X Ten 6
EGAD00001009480 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA530 passage 3 on DLP+ library A98240A HiSeq X Ten 4
EGAD00001009481 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient SA1096A, patient-derived xenograft SA1052D passage 1 on DLP+ library A98243B HiSeq X Ten 6
EGAD00001009486 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1050A passage 1, patient SA1234 on DLP+ library A98279A HiSeq X Ten 0
EGAD00001009487 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 2 on DLP+ library A95621B Illumina HiSeq 2500 1
EGAD00001009488 Single Cell Genome Sequence for Immortalized breast epithelium - BRCA2-/-; Tp53-/- cell line 184-hTERT-22 L9 112.109 cell line SA1055 on DLP+ library A95621A Illumina HiSeq 2500 3
EGAD00001009489 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient-derived xenograft SA1050D passage 1 on DLP+ library A95717B HiSeq X Ten 3
EGAD00001009517 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA533 Illumina HiSeq 2000 1
EGAD00001009518 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA409 Illumina HiSeq 2500 1
EGAD00001009519 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA420 Illumina HiSeq 2000 1
EGAD00001009520 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA296 Illumina HiSeq 2500 1
EGAD00001009521 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA597 Illumina HiSeq 2500 1
EGAD00001009522 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA232 Illumina HiSeq 2000 1
EGAD00001009523 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA211 Illumina HiSeq X 1
EGAD00001009524 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA230 Illumina HiSeq X 1
EGAD00001009525 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA234 Illumina HiSeq X 1
EGAD00001009526 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA278 Illumina HiSeq X 1
EGAD00001009527 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA101 Illumina HiSeq X 1
EGAD00001009528 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA212 Illumina HiSeq X 1
EGAD00001009529 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA214 Illumina HiSeq X 1
EGAD00001009530 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA224 Illumina HiSeq X 1
EGAD00001009531 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA225 Illumina HiSeq X 1
EGAD00001009532 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA226 Illumina HiSeq X 1
EGAD00001009533 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA228 Illumina HiSeq X 1
EGAD00001009534 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA229 Illumina HiSeq X 1
EGAD00001009535 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA231 Illumina HiSeq X 1
EGAD00001009536 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA233 Illumina HiSeq X 1
EGAD00001009537 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA237 Illumina HiSeq X 1
EGAD00001009538 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA271 Illumina HiSeq X 1
EGAD00001009539 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA277 Illumina HiSeq X 1
EGAD00001009540 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA284 Illumina HiSeq X 1
EGAD00001009541 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA399 Illumina HiSeq X 1
EGAD00001009542 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA294 Illumina HiSeq X 1
EGAD00001009543 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA285 Illumina HiSeq 2000 1
EGAD00001009544 Whole genome sequencing of normal sample for triple negative breast cancer patient SA101 Illumina HiSeq X 1
EGAD00001009545 Whole genome sequencing of normal sample for triple negative breast cancer patient SA211 Illumina HiSeq X 1
EGAD00001009546 Whole genome sequencing of normal sample for triple negative breast cancer patient SA212 Illumina HiSeq X 1
EGAD00001009547 Whole genome sequencing of normal sample for triple negative breast cancer patient SA214 Illumina HiSeq X 1
EGAD00001009548 Whole genome sequencing of normal sample for triple negative breast cancer patient SA224 Illumina HiSeq X 1
EGAD00001009549 Whole genome sequencing of normal sample for triple negative breast cancer patient SA225 Illumina HiSeq X 1
EGAD00001009550 Whole genome sequencing of normal sample for triple negative breast cancer patient SA226 Illumina HiSeq X 1
EGAD00001009551 Whole genome sequencing of normal sample for triple negative breast cancer patient SA228 Illumina HiSeq X 1
EGAD00001009552 Whole genome sequencing of normal sample for triple negative breast cancer patient SA229 Illumina HiSeq X 1
EGAD00001009553 Whole genome sequencing of normal sample for triple negative breast cancer patient SA230 Illumina HiSeq X 1
EGAD00001009554 Whole genome sequencing of normal sample for triple negative breast cancer patient SA231 Illumina HiSeq X 1
EGAD00001009555 Whole genome sequencing of normal sample for triple negative breast cancer patient SA232 Illumina HiSeq 2000 1
EGAD00001009556 Whole genome sequencing of normal sample for triple negative breast cancer patient SA233 Illumina HiSeq X 1
EGAD00001009557 Whole genome sequencing of normal sample for triple negative breast cancer patient SA234 Illumina HiSeq X 1
EGAD00001009558 Whole genome sequencing of normal sample for triple negative breast cancer patient SA237 Illumina HiSeq X 1
EGAD00001009559 Whole genome sequencing of normal sample for triple negative breast cancer patient SA271 Illumina HiSeq X 1
EGAD00001009560 Whole genome sequencing of normal sample for triple negative breast cancer patient SA277 Illumina HiSeq X 1
EGAD00001009561 Whole genome sequencing of normal sample for triple negative breast cancer patient SA278 Illumina HiSeq X 1
EGAD00001009562 Whole genome sequencing of normal sample for triple negative breast cancer patient SA284 Illumina HiSeq X 1
EGAD00001009563 Whole genome sequencing of normal sample for triple negative breast cancer patient SA285 Illumina HiSeq 2500 1
EGAD00001009564 Whole genome sequencing of normal sample for triple negative breast cancer patient SA290 Illumina HiSeq 2500 1
EGAD00001009565 Whole genome sequencing of normal sample for triple negative breast cancer patient SA294 Illumina HiSeq X 1
EGAD00001009566 Whole genome sequencing of normal sample for triple negative breast cancer patient SA296 Illumina HiSeq 2500 1
EGAD00001009567 Whole genome sequencing of normal sample for triple negative breast cancer patient SA399 Illumina HiSeq X 1
EGAD00001009568 Whole genome sequencing of normal sample for triple negative breast cancer patient SA400 Illumina HiSeq X 1
EGAD00001009569 Whole genome sequencing of normal sample for triple negative breast cancer patient SA409 Illumina HiSeq 2500 1
EGAD00001009570 Whole genome sequencing of normal sample for triple negative breast cancer patient SA420 Illumina HiSeq 2500 1
EGAD00001009571 Whole genome sequencing of normal sample for triple negative breast cancer patient SA533 Illumina HiSeq 2000 1
EGAD00001009572 Whole genome sequencing of normal sample for triple negative breast cancer patient SA597 Illumina HiSeq 2500 1
EGAD00001009573 Whole genome sequencing of normal sample for triple negative breast cancer patient SA997 Illumina HiSeq X 1
EGAD00001009574 Whole genome sequencing of normal sample for triple negative breast cancer patient SA998 Illumina HiSeq X 1
EGAD00001009575 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA416 Illumina HiSeq X 1
EGAD00001009576 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA400 Illumina HiSeq X 1
EGAD00001009577 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA290 Illumina HiSeq 2000 1
EGAD00001009578 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA288 Illumina HiSeq 2500 1
EGAD00001009579 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA299 Illumina HiSeq 2000 1
EGAD00001009580 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA095 Illumina HiSeq 2000 1
EGAD00001009581 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA415 Illumina HiSeq X 1
EGAD00001009582 Whole genome sequencing of normal sample for triple negative breast cancer patient SA718 Illumina HiSeq 2500 1
EGAD00001009583 Whole genome sequencing of normal sample for triple negative breast cancer patient SA720 Illumina HiSeq 2500 1
EGAD00001009584 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA718 Illumina HiSeq 2500 1
EGAD00001009585 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA720 Illumina HiSeq 2500 1
EGAD00001009586 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1017 Illumina HiSeq X 1
EGAD00001009587 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1026 Illumina HiSeq X 1
EGAD00001009588 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1027 Illumina HiSeq X 1
EGAD00001009589 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1028 Illumina HiSeq X 1
EGAD00001009590 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1040 Illumina HiSeq X 1
EGAD00001009591 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1064 Illumina HiSeq X 1
EGAD00001009592 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1065 Illumina HiSeq X 1
EGAD00001009593 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1069 Illumina HiSeq X 1
EGAD00001009594 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1073 Illumina HiSeq X 1
EGAD00001009595 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1074 Illumina HiSeq X 1
EGAD00001009596 Whole genome sequencing of normal sample for triple negative breast cancer patient SA576 Illumina HiSeq 2000 1
EGAD00001009597 Whole genome sequencing of normal sample for triple negative breast cancer patient SA610 Illumina HiSeq 2500 1
EGAD00001009598 Whole genome sequencing of normal sample for triple negative breast cancer patient SA992 Illumina HiSeq X 1
EGAD00001009599 Whole genome sequencing of normal sample for triple negative breast cancer patient SA994 Illumina HiSeq X 1
EGAD00001009600 Whole genome sequencing of normal sample for triple negative breast cancer patient SA095 Illumina HiSeq 2000 1
EGAD00001009601 Whole genome sequencing of normal sample for triple negative breast cancer patient SA288 Illumina HiSeq 2500 1
EGAD00001009602 Whole genome sequencing of normal sample for triple negative breast cancer patient SA299 Illumina HiSeq 2000 1
EGAD00001009603 Whole genome sequencing of normal sample for triple negative breast cancer patient SA415 Illumina HiSeq X 1
EGAD00001009604 Whole genome sequencing of normal sample for triple negative breast cancer patient SA666 Illumina HiSeq 2500 1
EGAD00001009605 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1065 Illumina HiSeq X 1
EGAD00001009606 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1064 Illumina HiSeq X 1
EGAD00001009607 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1026 Illumina HiSeq X 1
EGAD00001009608 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1069 Illumina HiSeq X 1
EGAD00001009609 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1017 Illumina HiSeq X 1
EGAD00001009610 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1027 Illumina HiSeq X 1
EGAD00001009611 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1073 Illumina HiSeq X 1
EGAD00001009612 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1074 Illumina HiSeq X 1
EGAD00001009613 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA576 Illumina HiSeq 2500 1
EGAD00001009614 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1028 Illumina HiSeq X 1
EGAD00001009615 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1040 Illumina HiSeq X 1
EGAD00001009616 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA992 Illumina HiSeq X 1
EGAD00001009617 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA610 Illumina HiSeq 2500 1
EGAD00001009618 Whole genome sequencing of normal sample for triple negative breast cancer patient SA416 Illumina HiSeq X 1
EGAD00001009619 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1070 Illumina HiSeq X 1
EGAD00001009620 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1070 Illumina HiSeq X 1
EGAD00001009621 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA997 Illumina HiSeq X 1
EGAD00001009644 Single Cell Genome Sequence for high grade serous ovarian carcinoma patient SA1105, patient SA1106 on DLP+ library A96168B HiSeq X Ten 5
EGAD00001009645 Single Cell Genome Sequence for Immortalized lymphoblastoid cell line GM18507 cell line SA928,Triple negative breast cancer patient-derived xenograft SA609 passage 2 patient-derived xenograft SA609 passage 2 on DLP+ library A96228A HiSeq X Ten 6
EGAD00001009646 Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA530 passage 3 on DLP+ library A98247A HiSeq X Ten 0
EGAD00001009650 This data set includes RNAseq from 38 follicular lymphoma tumours. All tumours were fresh frozen. Libraries were constructed by enriching for poly-A transcripts and sequenced as 75bp paired end reads on an Illumina HiSeq 2500 instrument. Illumina HiSeq 2500 38
EGAD00001009672 Whole genome sequencing of normal sample for triple negative breast cancer patient SA1058 Illumina HiSeq X 1
EGAD00001009673 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1058 Illumina HiSeq X 1
EGAD00001009674 Whole genome sequencing of tumour sample for triple negative breast cancer patient SA998 Illumina HiSeq X 1
EGAD00010000148 tumour samples using Affymetrix Genome-Wide SNP6.0 arrays Affymetrix_GenomeWide_SNP6.34 104
EGAD00010000500 Case samples using U133 Plus 2.0 Array Affymetrix_U133plus2- 35
EGAD00010000502 Case samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010000504 Control samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010001515 Nanostring PanCancer immune profiling data for The interface of malignant and immunologic clonal dynamics in high-grade serous ovarian cancer Nanostring 120
EGAD00010001542 Expression data for 42 PMBCL patient samples (32 IL4R WT cases and 10 cases with mutations in IL4R) Illumina DASL Assay 42
EGAD00010001980 Affymetrix SNP6.0 data for 341 DLBCL patients Affymetrix SNP6.0 341